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ABSTRACT 
Background: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents 
are the established standard of care for neovascular age related macular 
degeneration (nAMD), however there are currently limited data on long-term 
outcomes of this therapy. Ranibizumab is one such anti-VEGF agent administered to 
treat nAMD. 
Patients diagnosed with nAMD undergo regular clinic based follow-up as part of their 
treatment, often on a monthly basis.  Assessment during these appointments 
includes optical coherence tomography (OCT) scans, which can contribute to the 
detection of nAMD in the second eye. There is limited data on the symptomatic 
status, clinical presentation and outcomes of second eye nAMD whilst undergoing 
regular assessment for the first treatment eye under these conditions.   
Aims:  
The first aim of this thesis is to evaluate the long-term (5-year) outcomes of 
intravitreal ranibizumab (an anti-VEGF agent) in treating nAMD by examining a 
cohort within a real life clinic setting. The second aim is to compare the clinical 
presentation and treatment outcomes between the first and second treated eyes in 
patients that developed nAMD in both eyes, whilst under regular review for unilateral 
nAMD.  
Methods: A total of 208 patients (208 eyes) were included in a retrospective case 
series assessing the 5-year outcomes of nAMD treated with ranibizumab, entitled the 
long-term ranibizumab study (LTRS) (Chapter 3). Intervention was an individualised 
treatment model after three initial monthly loading doses. Visual acuity (VA), central 
macular thickness (CMT), qualitative OCT features, and adverse events (AE) were 
determined for each visit. Snellen VA was converted to Early Treatment Diabetic 
Retinopathy Study (ETDRS) letters for analysis.  
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To assess outcomes of second eyes diagnosed with nAMD, a retrospective case 
series entitled second-eye ranibizumab study (SERS) forms the second part of this 
thesis (Chapter 4).  Forty-five consecutive patients fulfilled the inclusion criteria of 
commencing treatment with ranibizumab in the first eye for nAMD between July 2007 
and March 2011,and subsequently developing nAMD in the second eye with at least 
12-months of follow-up in each eye. Treatment was administered under the same 
conditions as the LTRS. Snellen VA was measured, and OCT examination of both 
eyes at each visit assessed the presence of intra-retinal fluid (IRF) and sub-retinal 
fluid (SRF). Patient reported symptoms were recorded at every clinic visit.   
Paired t-tests were used to assess changes in VA and CMT over the study duration 
of the LTRS and SERS and two sample t- tests were used to evaluate VA differences 
between groups. Changes in VA compared to baseline were classified into the three 
categories: stable VA (loss or gain of ≤15 letters), improved VA (gain of >15 letters), 
or worse VA (loss of >15 letters). Linear regression was used to assess the effects of 
age, gender, number of injections, previous treatment, medical history, medications, 
and baseline VA on both VA and CMT changes. Chi-square test or Fisher’s exact 
test were used to measure proportions of patients with visual stability and OCT fluid 
free status at 12-months in the SERS.  
Results:  In the LTRS, mean VA improved by 1.9 letters after 1 year (p=0.020) and 
decreased by 2.4 letters over 5-years of the treatment (p=0.040). At the end of year 
5, 11.1% (23/208) of patients improved VA by more than 15 letters and 68.8% 
(143/208) of patients had stable VA, while 20.2% (42/208) patients lost more than 15 
letters. Patients with VA less than 35 letters (approximate Snellen VA 6/60) at 
baseline showed significant VA improvement after 5-years of treatment (mean 
increase 11.5 letters, p=0.01), whilst those that were between 70 and 85 letters 
(approximate Snellen VA 6/12 to 6/6) at baseline showed a mean decrease (-12.9 
letters, p=<0.001). There was a positive relationship between injection numbers and 
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VA improvement over the 5-years after adjusting for age and baseline VA 
(Regression coefficient 0.3, P<0.001). Mean CMT decreased by 28.3µm (p<0.01) 
over 5-years. Ocular AE, ocular serious adverse events (SAE) and systemic SAE 
occurred in 4.6%, 0.48% and 2%, respectively, during the follow-up period. Thirty-six 
per cent of patients did not require an injection in their 5th year of follow-up, whilst 
24% of patients required near monthly (10-12) injections in the 5th year. 
In the SERS, second treated eyes commencing treatment with good VA at baseline 
(defined as >76 letters, or Snellen VA approximately 6/9)) showed greater stability of 
vision at 12-months vs. first treated eyes (p=0.05). There was no significant 
difference in mean VA change between first and second treated eyes.  The 
proportion of OCT - fluid free eyes was higher amongst second treated eyes 
compared with first treated eyes at 12-months (70% vs. 40%, p=0.02). Intra-retinal 
fluid (IRF) was seen in 54% of second treated eyes at baseline compared with 84% 
in first treated eyes (p=0.01). Symptoms were absent in 54% of second treated eyes 
at baseline. The most common symptoms were “blurred vision” (28% of all patients) 
and metamorphopsia (11% of all patients). 
Conclusions: The visual gains achieved were not as significant as clinical trials, 
likely reflecting the differences in inclusion criteria of patients, and less rigorous 
follow-up and treatment.  Intravitreal ranibizumab was effective in maintaining vision 
in patients with nAMD and reducing macula thickness over 5-years using an 
individualised treatment regime in a real-world setting.. Ranibizumab is a safe drug to 
use over 5-years in a real-world clinical setting.  
In patients undergoing treatment for nAMD in the first eye, OCT screening of the 
second eye at each visit may be necessary to detect second eye nAMD in this at-risk 
population. A large proportion of patients are asymptomatic at diagnosis of second 
eye disease, and a significant proportion of patients were detected to have treatable 
subfoveal nAMD with OCT alone. Second eye disease detected and treated by such 
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a protocol showed a lower rate of IRF at baseline, suggesting early detection had 
occurred. Second eyes showed a higher rate of fluid free status at 12-months 
compared to the first treated eye, suggesting that early detection and treatment led to 
improved anatomical outcomes, potentially explaining superior VA outcomes. 
Patients commencing treatment in their second eye with good VA had better visual 
outcomes compared to those with worse VA.   
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CHAPTER ONE - Literature review 
 
1.1 - Introduction 
Neovascular age-related macular degeneration (nAMD, also known as exudative 
AMD) is the commonest cause of visual impairment in people over the age of 50 in 
the developed world. (1) Visual loss causes significant functional impairment  
(including deficiencies in reading and fine motor tasks) and is a risk factor for serious 
co-morbidities, conferring an increased risk of falls and subsequent hip fractures. (2-
4)  
Ranibizumab, (Lucentis, Genentech Inc. South San Francisco, CA) an anti-vascular 
endothelial growth factor (anti-VEGF) inhibitor is an effective treatment to reverse 
and stabilise visual loss secondary to nAMD. Several studies have shown that, 
untreated nAMD can lead to legal blindness in the affected eye within 3 years. (5) 
Since ranibizumab was introduced in 2006, it has revolutionised the treatment of 
nAMD. In Australia, ranibizumab has reduced incident blindness from newly 
diagnosed nAMD over a 2-year period by an estimated 72%. (6) 
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1.2 - Definition of age-related macular degeneration: 
Age-related macular degeneration (AMD) is a common, progressive bilateral 
degenerative condition of the central part of the retina (known as the macula) that 
affects older persons, resulting in a wide spectrum of central visual impairment. The 
macula allows patients to read and observe subtle changes in their environment 
(Figure 1). Bilateral macular function is important for depth perception and hence 
critical for fine motor tasks. 
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Figure 1 – Schematic diagram of macular degeneration -  This figure is taken from Arroyo 
JG. A 76-Year Old with Macular Degeneration. JAMA 2006; 295:2394. 
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1.3 - Classification of age-related macular degeneration 
Several methods of classification have been described for AMD, with epidemiological 
data reported utilising variations of each classification system.  The following 
classification is based on the presence or absence of a choroidal neovascular 
membrane (CNVM). 
1.3.1 - Dry age-related macular degeneration 
“Dry” (non-exudative, or non-neovascular) – comprises approximately 85% of 
diagnosed disease. (7) This encompasses a spectrum ranging from small drusen 
(asymptomatic to mild visual loss) to advanced geographic atrophy) (Figure 2) 
involving the fovea (generally with resultant Snellen visual acuity (VA) <6/60, 
classified as “legal blindness” in Australia).  
Drusen are localised deposits of extracellular material (mainly lipofuscin) lying 
between the RPE and the inner collagenous zone of Bruch’s membrane (7, 8) 
resulting from photoreceptor metabolism. In AMD, drusen is predominantly 
concentrated at the macula. (9). The term “drusen” is derived from the German word 
for geodes; cavities in rocks often lined by crystals  
In geographic atrophy (a manifestation of late stage AMD) Bruch’s membrane is 
markedly disrupted, with prominent RPE and photoreceptor atrophy (Figure 3) in 
addition to loss of inner retinal cell types including amacrine, horizontal and bipolar 
cells. 
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Figure 2 - Fundus photography of “dry” or non-exudative age-related macular degeneration: Panel A shows early disease (fine drusen), Panel B 
shows moderate disease (soft, coalescing drusen) and Panel C shows late disease (geographic atrophy) 
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1.3.2 – Neovascular age-related macular degeneration 
The neovascular type of AMD (also known as exudative, or wet AMD) accounts for 
15% of all AMD, yet is responsible for 90% of AMD associated blindness. (10) 
Angiogenesis is the process of new vessel formation sprouting from existing vessels. 
In the normal physiology of the eye, angiogenesis is important for tissue 
development, growth and repair. Pathological angiogenesis is the hallmark of nAMD. 
This occurs in the form of a CNVM (an ingrowth of new vessels from the 
choriocapillaris through Bruch’s membrane (the innermost layer of the choroid), 
fibrovascular pigment epithelial detachment (PED), an area of retinal angiomatous 
proliferation, (RAP resulting from growth from the deep capillary plexus of the retina 
growing downwards towards the RPE) or polypoidal choroidal vasculopathy (PCV, a 
branching choroidal network characterised by a bulb and stalk configuration of 
vessels with surrounding dilatation of the choroidal vessels.)  The result is damage to 
the photoreceptors by collections of fluid or blood leaked from these abnormal 
vessels.  Patients may also present with a disciform scar that indicates a previously 
active CNV (Figure 4, panel C) 
In contrast with non-exudative AMD, nAMD causes more severe and rapid vision loss 
and treatment has the potential to restore vision. 
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Figure 3 - Fundus photography and fluorescein angiography showing enlarging areas of RPE atrophy over a 2-year period, representing 
progressive geographic atrophy 
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Figure 4 - Fundus images illustrating soft drusen (A), choroidal neovascular membrane with sub-retinal haemorrhage (B) and resultant disciform 
scar (C). 
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1.3.2 - Grading the severity of age-related macular degeneration  
Severity of AMD may be graded based on clinical appearance of the macula with 
funduscopic examination or fundus photography (Table 1). In 2013 a panel of 26 
AMD experts published a consensus-derived clinical classification system using a 
modified Delphi process. (11) The fundus signs were based on a location of within 2 
disc diameters of the fovea in persons >55-years old. (11)  
 
 
Table 1 – Age-related macular degeneration severity and key features 
AMD Severity Key Features 
No AMD The absence of visible drusen or pigmentary abnormalities 
Normal Aging 
Changes 
The presence of small drusen only (also known as 
“drupelets” <63 μm in size) 
Early AMD 
The presence of medium drusen (>63μm and <125μm, 
correlating to the width of a retinal vein when exiting the 
optic disc) with an absence of pigment abnormalities. 
Intermediate AMD 
Large drusen (>125μm) or at least medium drusen 
associated with RPE abnormalities (hyperpigmentation or 
hypopigmentation)  
Late AMD Presence of neovascular AMD or geographic atrophy 
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The utilisation of this classification system in conjunction with the findings of the age-
related eye disease study (AREDS) aids prognostication of the 5-year risk of 
progression to late AMD. (12) This clinical tool helps to guide the physician on the 
need for more rigorous follow-up should the patient present in a high-risk category 
(Figure 11). It also aids in identifying a group of patients who were proven to derive 
the most benefit from vitamin supplementation, with the endpoint of decreasing the 
risk of progression to more advanced AMD. (13) 
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1.3.3 - Classification of neovascular age-related macular degeneration 
The method of anatomical nAMD classification was described by Gass et al. (14) and 
is based on the lesion characteristics as seen with fundus fluorescein angiography 
(FFA) characteristics and/or indocyanine green angiography (ICG). ICG is an 
alternative means of imaging the ocular circulation, with increased resolution of the 
choroidal circulation. The terminology is outlined in Figure 5, with the categories 
being “occult”, “classic” and “RAP”.   These descriptive terms are based on the filling 
patterns of the fluorescein within the neovascular lesion, which correspond to the 
anatomical position of these vessels in relation to the RPE layer.  In Australia, a FFA 
demonstrating subfoveal CNV secondary to AMD in patients >50 years old is 
required to access government subsidised anti-VEGF agents, namely ranibizumab, 
and aflibercept.  
Prior to the availability of modern anti-VEGF agents, the distinction between “occult” 
and “classic” lesions (described below) was important to guide treatment with 
verteporfin photodynamic therapy (PDT). The Verteporfin in photodynamic therapy 
study (VIP) and Treatment of Age-Related Macular Degeneration with Photodynamic 
Therapy (TAP) studies showed that PDT was only effective in CNV with a 
predominantly “classic” component. (15, 16)  In Australia, this is reflected by the 
pharmaceutical benefits scheme (PBS) funding approval criteria, where access to 
PDT is only permissible if the lesion is “shown by FFA to be subfoveal, and have a 
predominantly (>50%) classic appearance, in addition to a baseline VA of ≥6/60.”  
The Minimally Classic/Occult trial of the Anti-VEGF Antibody Ranibizumab in the 
Treatment of Neovascular Age-Related Macular Degeneration (MARINA) (17) and 
Anti-VEGF antibody for the treatment of predominantly classic choroidal 
neovascularisation in AMD (ANCHOR) (18) trials demonstrated that both classic and 
occult lesions responded well to ranibizumab, hence there is no such requirement 
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stipulating angiographic lesion type and visual acuity for access to ranibizumab in 
Australia. 
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Figure 5 - Classification of choroidal neovascularisation based on angiographic 
appearance 
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1.3.3.1 - Type 1 Choroidal neovascularisation (occult)   
The CNV is located beneath the RPE, and is termed “occult” as there is no clear 
leakage source identified on FFA.  There is ill-defined early hyperfluorescence, (due 
to blockage of fluorescein by the RPE, meaning that more fluorescein dye needs to 
accumulate before a lesion is apparent) with late stippled hyperfluorescence seen on 
FFA with indistinct margins, representing late leakage of fluorescein.   
The majority of CNV in nAMD is of the occult subtype, which is sub-categorised into 
fibrovascular pigment epithelial detachments (PED’s) (type 1 occult lesion, Figure 6) 
and late leakage of undetermined source (type 2 occult lesion). 
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Figure 6 - Occult Choroidal neovascular membrane (Type 1 choroidal 
neovascularisation) imaging – fundus photo (A), early (B), mid (C) and late (D) phase 
fluorescein angiography, demonstrating an increasing area of diffuse hyperfluorescence, 
indicating diffuse leakage. Corresponding optical coherence tomography (OCT) illustrating 
sub-retinal fluid (arrow, E)
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1.3.3.2 - Type 2 choroidal neovascularisation (classic)  
In this subtype, the CNVM has penetrated the RPE and lies above it (in the sub-
retinal space) resulting in early hyperfluorescence on FFA that progressively 
increases in size and intensity during the study. The margins of the lesion are well 
defined in the later phase of the angiogram (Figure 7). Classic lesions typically lead 
to a more rapid deterioration of vision compared to occult lesions (18), hence their 
identification is important to ensure treatment is commenced promptly. Furthermore, 
this subtype was shown to be more responsive to previous treatment modalities 
including PDT. (15, 16) 
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Figure 7 - Classic choroidal neovascularisation (Type 2 choroidal neovascularisation) 
imaging: fundus photo (A), early (B), mid (C) and late phase FFA (D), showing early 
hyperfluorescence with well demarcated borders, and SD-OCT illustrating sub-retinal fluid (E, 
arrow).
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1.3.3.3 - Type 3 choroidal neovascularisation: (Retinal angiomatous proliferation)  
This type of neovascularisation originates from the retinal circulation, limited to the 
neurosensory retina in early stages, and merging with the choroidal circulation in 
advanced disease. (19) It is best demonstrated using ICG angiography, however can 
be visualised with FFA (Figure 8). The term “Type 3 CNV” was popularised by 
Freund in 2008. (20) The incidence of RAP lesions is influenced by ethnic 
background, with a much lower rate of this CNV subtype in Asians compared to 
Caucasian populations. (21)
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Figure 8 – Retinal angiomatous proliferation lesion (Type 3 choroidal 
neovascularisation) - fundus photo showing intraretinal haemorrhage at the fovea (A), 
fundus fluorescein angiography shows diffuse leakage (B-C), and optical coherence 
tomography shows intra-retinal cysts (D). 
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1.3.3.4 - Polypoidal Choroidal Vasculopathy 
Polypoidal choroidal vasculopathy (PCV) is an additional subtype of nAMD that is 
often included in the classification of nAMD, and is more prevalent in Asia.  Despite 
sharing some common genetic traits with AMD, (specifically the 
LOC3877715/HTRA1 variant) (22) several authors regard this condition as a 
separate entity, evidenced by its markedly different response to PDT and anti-VEGF 
agents. (23) (24) In contrast, many authorities have subsequently considered it to be 
a form of nAMD (25). This lesion is characterised by a branching choroidal network 
with surrounding polypoidal (resembling a small growth, with a stalk) dilatation of the 
choroidal vessels, leading to recurrent serous leakage and haemorrhage. (26) The 
lesion is best visualised with ICG angiography. (23) Polypoidal choroidal 
vasculopathy must be considered in the differential diagnosis when treating a patient 
of Asian descent, evidenced by a recent study by Maruko et al. which found a 54.7% 
prevalence of PCV in eyes of Japanese patients who had been diagnosed with AMD, 
(27) highlighting the likelihood of widespread under-diagnosis of this condition. 
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1.4 Epidemiology 
 
1.4.1 - The global impact of macular degeneration  
Age-related macular degeneration is the leading cause of blindness in western 
countries for those aged over 55, eclipsing other blinding conditions including 
glaucoma, diabetic retinopathy and cataract. (28-30) It is estimated to affect 30 – 50 
million individuals worldwide. (31-35) In the USA approximately 15 million people 
have “dry” AMD whilst 1.7 million people have nAMD, representing 10-15% of all 
AMD.  The estimated incidence of new cases of exudative AMD in the USA is 
200,000, where it is the leading cause of blindness, with an expected two-fold 
increase in prevalence by 2020. (32, 36)  
Comparisons of the scope of patients’ affected by this disease can be made with 
cancer (2007 prevalence of 12 million in the US) (37) and Alzheimer’s disease (2007 
prevalence of 5 million in the US). (38) In the UK, prevalence of nAMD in those aged 
50 years or more was 10% in 2012. (39) UK annual incidence of nAMD was 2.3 per 
1000 in women, and 1.4 per 1000 in men, totalling 3.7 per 1000 persons in 2012. 
(39) 
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1.4.2 - Macular degeneration in Australia: 
Consistent with much of the developed world, macular degeneration is the leading 
cause of blindness in Australia, causing 50% of all legal blindness. (40)  
Prevalence of age-related macular degeneration: 
An estimated 1 million people over 50 (14.3% of Australians over 50) have AMD, with 
the numbers of each subtype shown in Figure 9.   The prevalence of AMD is 4 times 
greater than that of dementia, and half that of diabetes, (41) and therefore a major 
public health concern.  
Incidence and Prevalence of neovascular age-related macular degeneration: 
In 2010, 110 000 Australian patients had nAMD. There were 7622 new cases 
diagnosed in 2014 leading to treatment with anti-VEGF agents of ranibizumab or 
aflibercept  (Department of Human Services Medicare Pharmacy Claims database, 
accessed April 2015) giving an incidence rate of 0.036% or 3.6 per 1000 persons. 
The number of new cases of nAMD in Australia has remained reasonably stable at 
7000 to 8000 cases between 2007 and 2014. (Table 1) 
Treatment frequency and duration: 
Recent prevalence data from the Department of Human Services reports that in 
2014, 36,739 patients received at least one intra-vitreal injection of an approved 
agent for nAMD (ranibizumab or aflibercept) and 249,722 injections were dispensed 
in total (Table 1).  Approximately 3000 patients are into their seventh year of 
treatment (39% of patients initiated with therapy in 2007) indicating that ongoing 
treatment is required for many patients, and therefore the long-term efficacy and 
safety is of importance. This will be addressed in the long-term ranibizumab study 
(LTRS).   
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Projected rates: 
Age-related macular degeneration prevalence rate in Australia is projected to 
increase to 1 700 000 by 2030 driven by an aging population. (41) 
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Figure 9 - 2010 estimated prevalence of age-related macular degeneration in Australia 
in those age > 50 years. *For these statistics, “dry AMD” refers to late, atrophic stage 
(Geographic Atrophy) with a visual acuity of 6/12 or worse. 
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Table 2 – Summary of age-related macular degeneration treatment in Australia, and utilisation of ranibizumab and aflibercept.  *The figure for 2007 
represents the first five months of listing. Source: Department of Human Services Medicare Pharmacy Claims database, accessed April 2015 
 
 
 
 
 
 
 
 
New 
patients 
Prevalent 
patients 
Prescriptions 
supplied 
Injections 
supplied 
Calculated 
injections per 
prevalent patient 
2007* 7,478 7,478 17,482 18,492 2.47 
2008 8,205 14,320 59,786 63,177 4.41 
2009 8,125 18,889 93,087 98,612 5.22 
2010 7,654 22,834 130,814 140,245 6.14 
2011 7,097 26,132 160,194 172,548 6.6 
2012 6,874 29,269 188,027 203,751 6.96 
2013 7,765 33,347 208,919 227,193 6.81 
2014 7,622 36,739 229,083 249,772 6.8 
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1.4.3 - Incidence of second eye neovascular age-related macular degeneration 
There is a large reported range of incidence rates for nAMD being diagnosed in the 
second eye.  A meta-analysis of 53 studies (including 28 randomised trials) by Wong 
et.al. found a rate of 12.2% at 12-months and 26.8% by 48 months. (5) Epidemiology 
studies have reported incidence rates of second eye nAMD in patients with unilateral 
nAMD ranging between approximately 12% and 22% at 2 years. (42) Five-year 
retrospective analysis of second eyes in the macular photocoagulation study (MPS) 
without CNV at baseline showed a 25.7% incidence of CNV at 5-years, therefore an 
extrapolated annual incidence rate of approximately 6% per year was noted, 
whereas the sub-macular surgery trials reported a CNV rate of 12.8% per year in 
second eyes. (43) (44) MARINA and ANCHOR trials reported 2-year incidence rates 
between 23.8% and 36.3% in both treatment and control arms, (42) Although this is 
the highest rate reported, it is likely the most accurate; reflecting earlier and more 
accurate detection of nAMD due to the rigorous and regular assessments including 
the use of optical coherence tomography (OCT) mandated by a trial protocol.  
There is a suggestion of ethnic variation in the incidence of second eye CNV, with 
AREDS prospective 5-year data reporting a 30.8% rate in a Caucasian population, 
(45) compared to 12% in a Japanese population. (46) This lower incidence may be 
partially related to differences in the complement factor-H genotypes of Japanese 
patients. (47) 
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1.4.4 - Timing of neovascular age-related macular degeneration developing in 
the second eye relative to the first eye 
Gudnadottir et.al (48) reported a subset of 65 patients (from a cohort of 2220 
individuals, with a maximum follow-up duration of 13 years) who developed second 
eye nAMD following diagnosis in the first eye.  They found a mean time interval of 
2.5 year between eyes, and a median time of 1.8 years.  
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1.5 - Population screening for age-related macular degeneration 
 
Utility of the Amsler Grid as a diagnostic tool: 
A “screening test” can be defined as a population based strategy to target a test 
towards an “at risk population” that has a high positive predictive value. Although 
there is no proven screening population based screening program for AMD, some 
public health policies have promoted the use of an Amsler grid as a screening tool for 
all patients over the age of 50.  
The purpose of the Amsler Grid is to detect new metamorphopsia or scotoma. (49) 
The patient is asked to gaze at the centre of the grid as frequently as possible. 
(Figure 10) Its advantages include minimal cost of production, ease and speed of 
administration, and the ability of the test to be self-administered by the patient at 
home. 
Schlaegel et.al. in 1968 (50) was one of the first advocates of using an Amsler grid to 
monitor central vision with the aim of detecting macular disease, and thus it is a 
practice over 40 years old.  Its ability to detect visual disease has remained doubtful 
in several studies (51) and many clinicians feel that it is not a sufficiently sensitive 
instrument for monitoring vision. (52, 53) Reasons for its shortcomings include likely 
non-compliance by patients (54) and physiological adaptation by the brain in the form 
of a “cortical filling in” mechanism leading to a failure to perceive small lesions. (55) 
Despite its limitations, the Amsler grid remains the most commonly used home tool 
for screening for the incidence and progression of macular disease, and patients are 
routinely asked to present for medical care should they notice a change in their vision 
using this tool. 
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Figure 10 - Amsler Grid - Left panel shows the grid viewed without macular disease, whilst 
the right panel illustrate a paracentral scotoma and metamorphopsia seen in macular 
degeneration.  
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1.6 - Ocular risk factors for neovascular age-related macular 
degeneration: 
 
1.6.1 - Ocular signs of age-related macular degeneration observed on clinical 
examination: 
The presence of large drusen (>125um) and pigmentary changes on funduscopic 
examination or fundus photography have been identified as risk factors for 
developing advanced AMD in the AREDS study. (13) This culminated in a severity 
assessment scale, which is designed for use by a clinician to quickly assess the 5-
year risk of developing advanced AMD (Figure 11). (12)  
Advanced AMD (either nAMD or geographic atrophy) that presents in one eye has 
been shown to be a strong predictor of progression to advanced AMD in the 
remaining eye without AMD (8.6% in eyes with advanced AMD in the second eye vs. 
0.7% in eyes without advanced AMD in the second eye at 10-years following 
baseline) (56) This increased rate of developing nAMD is also seen in eyes with early 
AMD changes, such as small to intermediate size drusen, and RPE abnormalities, 
where the second eye has advanced AMD. Up to 76% of such eyes will develop 
nAMD after 10-years (56).  Both these findings suggest that the presence of nAMD in 
one eye will likely result in the same disease process in the remaining eye, and is a 
reminder that nAMD can be considered a bilateral process.  
 50 
 
 
 
 
Figure 11 - Algorithm for stratifying risk of progressing to late age-related macular 
degeneration at 5-years, based on funduscopic signs. (12) Taken from Ferris et.al, 2005 
– A simplified severity scale for age-related macular degeneration: AREDS Report No.18. 
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1.7 Natural history of neovascular age-related macular degeneration: 
 
Progression of early age-related macular degeneration to neovascular age-related 
macular degeneration: 
Chew et al. (56) examined long-term (10-year) outcomes of 3549 participants and 
addressed the natural history of patients who present with early AMD. (56) Those 
treated with the AREDS vitamin supplementation formula were found to have a lower 
rate of CNV, but not GA at 10 years. 
Consistent with the findings from the AREDS Report No.18, (12) patients classified in 
the most severe group of AMD had high rates of progression to advanced AMD by 
10 years (48.1% for nAMD and 26.0% for GA.)  There was a positive correlation 
between the severity of AMD at presentation and risk of late AMD at 5-years.   
 
Progression of neovascular age-related macular degeneration: 
Prior to modern effective treatments for nAMD, several prospective natural history 
studies were ethically permissible, including the placebo arm for the MARINA trial for 
occult sub-foveal CNV, a pivotal study establishing anti-VEGF therapy as the modern 
standard of care. (17) Once nAMD has developed, the natural history of the disease 
without treatment leads to legal blindness.    
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1.7.1 - Rate of visual loss: 
Wong et.al published a comprehensive meta-analysis examining the natural history 
of untreated nAMD from 53 interventional studies, including 28 randomised clinical 
trials.  The average VA loss was 1 line of logMAR VA at 3 months, increasing to 4 
lines at 24 months compared to baseline.  The proportion of patients with VA 
deterioration compared to baseline was 45% at 3 months, and 81.1% at 2 years.  
Legal blindness (defined as logMAR VA >1.0 or Snellen VA <6/60), was noted in 
19.7% of patients at baseline 50.3% at 3 months and 77.6% at 3 years. (5) There 
was great variation in the blindness rates between studies within the meta-analysis. 
In contrast, Bressler et.al. reported outcomes from 103 582 patients with nAMD, and 
found a much lower rate of legal blindness at 16% within 2 years of diagnosis without 
treatment. (57) The data must be interpreted with caution, as some patients were 
included in the study at a variable time since their onset of disease, therefore pre-
existing visual loss due to nAMD, prior to study inclusion may not be included. 
Despite this caveat, these findings highlights the severe and swift functional deficit 
that results from untreated exudative AMD, and provide a means of extrapolating 
long-term visual outcomes of untreated disease.   
Establishing the rate of vision loss is important, as the timing of initiating anti-VEGF 
therapy with nAMD for a patient with good VA (e.g. 6/6 Snellen) remains 
controversial. An argument to treat early is to cause CNV regression before 
permanent retinal structural damage occurs, minimising irreversible visual loss. An 
argument against treatment surrounds the potentially unnecessary exposure to the 
risk of developing iatrogenic endophthalmitis and other ocular serious adverse 
events (SAE) (discussed in 1.14 - Safety concerns of anti-VEGF agents and its 
administration).
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1.7.2 - Risk of blindness after reporting symptoms  
Information regarding patients’ progression following symptoms for nAMD is scarce. 
Walsh et.al. reported the proportion of patients progressing to legal blindness 
(Snellen VA <6/60) following symptomatic presentation of foveal involving nAMD.  He 
reviewed 476 patients and related the length of symptoms vs. the proportion of 
patients who were legally blind. (58) Walsh’s data suggests that visual deterioration 
occurred rapidly after nAMD symptoms were noticed, with 32% of eyes legally blind 
after 1 month of symptoms and 45% after 2 months of symptoms. (Figure 12) 
Therefore, it follows that early detection and treatment of both symptomatic and 
asymptomatic disease would improve visual outcomes.  Data regarding progression 
of asymptomatic disease is lacking. 
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Figure 12 - Correlation of duration of symptomatic neovascular age-related macular 
degeneration related visual loss and percentage of cases with visual acuity less than 
6/60 Adapted from Walsh et.al (58) 
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1.8 - Clinical presentation of age-related macular degeneration 
In patients >50 years of age, several small hard drusen (<63um diameter) are often a 
normal macular finding and represent age-related changes. (59) These do not affect 
subjective vision, unlike “soft” drusen that can affect vision.  Soft drusen and RPE 
changes are signs of moderate macular degeneration and are both risk factors for 
progression to late AMD. (12)  
Patients may present for care at various stages of disease ranging from 
asymptomatic drusen at the macula to massive sub-foveal haemorrhage from nAMD 
causing acutely impaired vision. Furthermore, they may initially present with early 
and intermediate AMD, and progress to nAMD without any noticeable visual 
changes. (60) There is debate as to whether AMD pathogenesis involves linear 
progression from early stages to the late AMD stages.  Neovascular AMD and GA 
may represent two distinct diseases with distinct biochemical pathways, rather than 
representing the end-stage sequelae of the same condition. (61) 
 
1.8.1 - Symptoms of neovascular age-related macular degeneration: 
There are a range of presenting symptoms for nAMD, including a central scotoma 
(Figure 13), or distortion of central vision (metamorphopsia, often expressed as a 
warping or distortion of straight lines (Figure 10). Increased glare, and decreased or 
asymmetric contrast sensitivity has been described. Micropsia (minification of 
objects) can occur, as can floaters or generalised blurring of the visual field (62).  
There are few studies reporting symptoms in macular disease, however blurred 
vision and distortion were the most commonly reported first symptoms of a macular 
CNV in a study by Fine et.al. (54) Furthermore, there is limited published data on the 
symptoms of early nAMD. 
 56 
Presentation for ophthalmic assessment can be delayed in patients, who either do 
not notice early changes in their vision, or attribute them to other ocular conditions 
such as cataracts, deferring assessment. (58) There is little data describing the 
outcomes in these asymptomatic patients who may have treatable sub-clinical nAMD 
lesions. 
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Figure 13 – Neovascular age-related macular degeneration patient with simulated loss 
of vision with a central scotoma. 
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1.8.2 - Signs of neovascular age-related macular degeneration 
A disciform scar (Figure 4, right panel) represents the endpoint of a previously active 
CNV with retinal haemorrhage. Visible haemorrhage in the posterior pole is only 
found in a small proportion of patients (Figure 14). (31) 
The presence of “soft drusen” at the macula is a prominent finding in those with 
AMD, and is a risk factor for developing nAMD in a Caucasian population (Figure 
15). (45) A distinct lack of soft drusen has been noted in Asian patients who develop 
CNV, evidenced by the findings of Uyama et.al. who reported on precursor signs of 
second eye nAMD in a Japanese cohort. Serous PED was found to be the most 
common predisposing lesion for nAMD (58%) with soft drusen second (18%).  (46) 
Further discussion on the imaging features of nAMD is provided in subsection 1.10.  
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Figure 14 - Macular haemorrhage secondary to neovascular age-related macular 
degeneration seen with fundus photography 
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Figure 15 – Regressing calcified drusen and pigmentary changes at the macula   
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1.9 - Diagnosis of neovascular age-related macular degeneration   
For many years the gold standard for diagnosing and monitoring CNV in nAMD has 
been FFA, which is usually conducted following a funduscopic examination from an 
ophthalmologist showing signs suggestive of active nAMD.   A FFA is also indicated 
if a patient reports new visual symptoms suggestive of macular pathology, including 
metamorphopsia, difficulty reading, or generalised blurring of vision. This latter 
practice was based on recommendations from the MPS study in 1993, (44) and 
remains largely unchanged in recently published guidelines by the European Society 
of Retina Specialists (EURETINA) in 2014. (63) 
Fundus fluorescein angiography is a time consuming, invasive investigation, with a 
1:222000 risk of potentially fatal anaphylaxis (64), all factors driving the search for an 
alternative imaging modality. 
Furthermore, limitations with FFA’s ability to detect early CNV have been reported. 
This is evidenced by histopathological analysis of resected CNV membranes that 
contained fenestrated sub retinal vessels consistent with CNV, without demonstrating 
leakage on angiography. (65) Additionally, the size of surgically removed CNV 
membranes have been found to be 50% larger than their measured angiographic 
size, suggesting that a small CNV could remain angiographically silent. (66) FFA 
remains the preferred modality for diagnosis of nAMD, however progress may be 
effectively monitored by OCT. (67)  
There is recent interest and research in OCT angiography (OCT-A), which provides a 
non-invasive means to provide a three-dimensional map of the retinal and choroidal 
vasculature. It compares the differences between sequential OCT scans taken at the 
same site to construct a map of blood flow at a fixed point in time.  As such, OCT-A 
cannot show leakage of fluid like a FFA, however it may more clearly delineate the 
size of a CNV, especially in Type 1 CNV compared with FFA.  Current limitations 
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include a small field of view, and increased potential for artefacts compared to FFA. 
(68) Whilst the technology has not been adopted for widespread clinical use at this 
stage, this modality shows promise in complementing or displacing FFA as the 
diagnostic modality of choice for nAMD in the future.  Early studies have shown that 
OCT-A is able to reliably detect Type 1 and Type 2 CNV in nAMD, with a case 
illustrated in Figure 16. (69)
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Figure 16 – Adapted from Moult 2014 – Ultrahigh – speed swept-source OCT-A in exudative age-related macular degeneration: 87 year-old patient 
with nAMD and active CNV lesion. En face slice of the OCT angiogram at the depth of the choriocapillaris, with the “classic” (yellow) and “occult” (red) 
components of the CNV outlined, and arrows pointing to movement artefact, (E) Early phase FFA with arrows pointing to the classic lesion. (F) Early phase 
ICG with arrows pointing to the “occult” CNV. (G) Late phase FFA with arrows pointing at stippled hyperfluorescence. (H) OCT retinal thickness map. (I) 
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1.9.1 - Fundus fluorescein angiographic findings in neovascular age-related 
macular degeneration 
In addition to describing the pattern of leakage, other characteristics can be observed 
on FFA to determine the presence of a CNV.  The following criteria were used by the 
reading centre for the MARINA and ANCHOR trials to indicate conversion of the 
second eye from non-exudative to nAMD: (42) The presence of any of the following 
characteristics on FFA was considered evidence of nAMD. 
 
- Neovascular or exudative characteristics 
- Classic choroidal neovascularisation subtype (Type 2 CNV, Figure 7) 
- Fibrovascular PED 
- Serous pigment epithelial detachment 
- Serous sensory retinal detachment 
- Other occult choroidal neovascularisation or late leakage of undetermined 
source (Figure 8) 
- Macular haemorrhage (Figure 14) 
- Fibrous tissue 
- Photocoagulation scar 
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1.9.2 - Optical coherence tomography in neovascular age-related macular 
degeneration 
Optical coherence tomography is a non-invasive, imaging modality that utilises 
interferometry (a technique that measures the reflectance patterns of light, allowing a 
cross-sectional reconstruction of ocular structures, particularly the retina and 
choroid).  In addition to providing anatomical contours of tissues, it is well suited to 
the measurement of retinal thickness; a feature that has helped guide management 
of nAMD. It has been widely adopted since the mid 2000’s in clinical practice, with 
early devices utilising Time-Domain OCT (TD-OCT). (70) This technique generates 
reflectance patterns between the tissue of interest and a moving reference mirror, 
and has been used in the majority of clinical trials involving anti-VEGF agents.  Its 
major limitation relates to the image acquisition time, utilising 768 A-scans, leading to 
limited image resolution and increased artefacts compared to the next generation of 
OCT technology, termed Spectral-Domain OCT (SD-OCT) which utilises up to 65536 
A-scans.  This technical limitation has contributed to the finding that TD-OCT was 
less sensitive than FFA for detecting new onset nAMD,(71) whereas recent studies 
have shown that SD-OCT may be more sensitive that FFA, Amsler Grid, or 
preferential hyperacuity perimetry testing for detecting early nAMD.  (71) Secondly, 
automated segmentation errors of the retinal layers utilising a TD-OCT are well 
known, especially with severe macular conditions such as nAMD. (69)(72) This issue 
is further discussed in the methods section, Chapter 2.  
Although the resolution of OCT images has improved markedly in the last decade, 
and there may be a future role for OCT in the diagnosis of nAMD (particularly with 
OCT-A) FFA is currently the preferred modality for initial diagnosis. OCT is the 
preferred imaging modality for assessing treatment response via anatomical features 
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including the presence of IRF, sub-retinal fluid (SRF) and the central macular 
thickness (CMT) to help guide the ongoing need for anti-VEGF treatment.
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1.9.2.1 - Features of neovascular age-related macular degeneration imaged on 
optical coherence tomography - (73)   
1. Fibrovascular pigment epithelial detachment (Figure 17). 
Classically appear as broad elevations of the RPE band, accompanied by 
serous exudate and/or haemorrhage. Enhanced depth OCT imaging shows 
solid layers of material with medium reflectivity within the PED, interspaced 
with hypo-reflective clefts.  
2. Serous pigment epithelial detachment (Figure 18). 
Smooth, sharply demarcated, dome shaped RPE elevation on OCT, visible 
with fundoscopy.  
3. Haemorrhagic pigment epithelial detachment 
Similar OCT appearance to serous PED, with marked shadowing of Bruch’s 
membrane 
4. Retinal angiomatous proliferation (Figure 19) 
Classically shows frank cystoid macular oedema overlying a PED, with SRF).  
5. Sub-retinal hyper-reflective material / disciform scars 
An amorphous lesion of medium to high reflectivity above the RPE, 
representing the CNV membrane during a highly vascular initial growth 
phase.  This evolves into a primarily fibrous lesion, leading to disciform scar 
appearing as a hyper-reflective lesion.  Loss or thinning of the overlying 
photoreceptor layer is also common. 
6. Presence of sub-retinal fluid / Serous retinal detachment 
Pockets of hypo-reflective spaces between the RPE and the neurosensory 
retina. (Figure 7) A homogenous hypo-reflective space is consistent with 
serous exudate, sparsely hyper-reflective spaces are consistent with fibrin or 
red blood cells.  
 
7. Presence of intra-retinal fluid 
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A hallmark event of nAMD is the disruption of the external limiting membrane 
– photoreceptor complex by invasion and proliferation of the CNV lesion into 
the retina.  This results in leakage of fluid into the neurosensory retina, 
manifesting as retinal thickening, or cystoid hypo-reflective spaces. (74) 
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Figure 17 – Fibrovascular pigment epithelial detachment – increased reflectivity 
underlying broad retinal pigment epithelial detachments.  
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Figure 18 – Serous pigment epithelial detachment – smooth dome shaped retinal pigment 
epithelial elevation. 
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Figure 19 – Retinal angiomatous proliferation – intra-retinal fluid overlying pigment 
epithelial detachments. 
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1.9.3 – Indocyanine green angiography 
The angiographic features of PCV on FFA can be indistinguishable from occult or 
classic CNV, (26) highlighting the role of ICG in obtaining a definitive diagnosis.  
Polypoidal choroidal vasculopathy classical features include exudative and 
haemorrhagic PED.  Up to 85% of eyes with large haemorrhagic and exudative 
neurosensory detachment and PED are diagnosed with PCV with ICG angiography.  
Due to the neurosensory detachment component, PCV can also masquerade as 
central serous chorioretinopathy. Typical ICG angiography findings include a 
branching vascular network comprising of polypoidal structures and variably sized 
vascular channels (26) seen in the following case study (Figure 20, Panels C-D). 
Additionally, polypoidal lesions are typically located at the edge of a PED. A 
technique of utilising both FFA and ICG angiography in the same testing session can 
aid in diagnosis and delineating the laser spot size used with therapeutic PDT, Figure 
21 illustrates the use of ICG in showing treatment response 3-months later, with no 
leakage from the polypoidal lesions.
 73 
 
 
 
Figure 20 – Polypoidal choroidal vasculopathy case:  72 year old male presented with 1 month of left sided visual field loss, VA 6/18 Left eye, diagnosed 
with IPV. Fundus photo of the affected eye (A).  Fluorescein angiography with leakage of fluorescein within the foveal avascular zone, similar in appearance 
to occult CNV (B). Early phase and late phase ICG angiography at diagnosis showing polyps.(C-D).  Optical coherence tomography showing intra-retinal 
cysts and thickening (E).  
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Figure 21 – Polypoidal choroidal vasculopathy case 3 months following photodynamic therapy, visual acuity 6/4.8. Late phase indocyanine green 
angiography pre-treatment (A).  Late phase indocyanine green angiography with no leakage seen 3 months post photodynamic therapy (B). Optical 
coherence tomography showing resolution of the intra-retinal cysts and foveal thickening 3 months post treatment aligned with Figure 16E (C)
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1.10 – History of treatment of neovascular age-related macular 
degeneration 
1.10.1 - Thermal laser  
Since the 1980’s, this method of destructive photocoagulation was an early treatment 
modality available for exudative macular degeneration, and remained the only 
clinically proven means of treatment for almost two decades. The MPS group 
concluded that the patients with classic, small, extra-foveal or juxta-foveal CNV 
benefited the most from this treatment. This subgroup represented a small proportion 
of patients with nAMD and although initial outcomes were superior to observation 
alone, both groups had poor vision at 5-years of follow-up. (75, 76) An immediate 
central scotoma would result following laser application, progressively enlarging over 
subsequent years as a result of laser-induced atrophy that often expands to include 
the fovea. Other adverse effects included RPE rupture, and sub-retinal or vitreous 
haemorrhage. (26) The aim of treatment was to arrest the CNV progression resulting 
in stabilisation of the VA. Improvement of VA did not occur for the majority of 
patients. Thermal laser is no longer offered to patients for sub-foveal nAMD, as new 
treatment modalities are more effective at preserving vision.    
 76 
1.10.2 - Photodynamic therapy  
Photodynamic therapy (PDT) was the next major advancement in treatment for 
nAMD, beginning in the late 1990’s. It was a promising treatment option at the time. 
Prior to anti-VEGF agents, it was considered to be a treatment option for “classic” or 
Type 2 CNV membranes, hence early anti-VEGF randomised trails including 
ANCHOR (77) and RhuFab V2 Ocular Treatment Combining the Use of Visudyne to 
Evaluate Safety (FOCUS) (78) targeting classic lesions included a control arm 
utilising PDT.  
This treatment modality uses a laser with a wavelength of 689nm to activate 
Verteporfin (Visudyne; Novartis Pharmaceuticals Corp, East Hanover, NJ) a 
substance that preferentially adheres to capillary endothelial cells of CNV 
membranes.  A laser pulse of 50 J/cm2 intensity, 600mW/cm2 for 83 seconds, using 
a spot size of 1000um more than the largest CNV diameter (measured from FFA) 
destroys CNV vessels, whilst leaving normal vessels intact. (79) 
Studies assessing the efficacy of PDT found that predominantly “classic” or Type 2 
neovascular membranes responded best, in patients with visual acuity of 6/60 or 
better. (15) Additionally, it conferred an increased benefit over thermal laser, in that 
larger lesions (up to 5400um in diameter) and subfoveal lesions showed some 
benefit, expanding the potential treatment pool to 30% of all nAMD related CNV. This 
was a major reason to search for another treatment that could treat a higher 
percentage of CNV lesions. These criteria are still reflected on the Australian PBS 
approval application for nAMD treatment. PDT can still be used for “classic” lesions 
in the rare situation of a patient refusing treatment with anti-VEGF therapy.  
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1.10.3 - Other treatments less widely adopted 
Several surgical treatment modalities for nAMD underwent clinical trials in the past, 
including excision of the neovascular tissue, (80) subfoveal surgery with cell 
transplantation, (81) macular translocation, (18-23), radiation treatment (24-27) and 
trans-pupillary thermal therapy. (28) The role of CNV excision via pars plana 
vitrectomy vs. laser photocoagulation was explored in the Submacular Surgery 
Trials, a prospective multicentre clinical trial. (82) Surgery was not found to be 
superior to laser, possibly related to the collateral damage caused by the surgical 
trauma to surrounding RPE responsible for the nutritional needs of the macular. (83) 
The next evolution of treatment to address this issue was to combine CNV extraction 
with relocating the macular to a bed of undamaged RPE, either by folding the scleral, 
or performing a 360 degree retinotomy.  Some trials showed VA gains in excess of 3 
early treatment of diabetic retinopathy study (ETDRS) lines, however many patients 
experienced post-operative diplopia. (83) 
Intravitreal triamcinolone acetonide (IVTA, a corticosteroid) was a promising therapy 
for nAMD.  Conflicting evidence emerged, as animal trials and early clinical reports 
suggested a benefit of a single injection (84, 85) whilst later studies suggested no 
difference in visual outcomes when compared to placebo at 12-months.  (86) Gillies 
et.al. did find evidence CNV growth retardation in the first 3 months following IVTA 
therapy, possibly explained by the bioavailability of IVTA in the eye, however this 
effect was not maintained at 12-months. (86) IVTA was later combined with PDT 
where its main benefit was to reduce the amount of verteporfin treatments. (87) 
Concerns of the adverse events related to IVTA, including increased progression of 
cataract, and mild to moderate intra-ocular pressure rise (88) also contributed to its 
position as a second-line treatment for nAMD. 
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It was clear that existing therapeutic options were of limited benefit, and targeting 
VEGF directly was the next major advancement in treatment.  
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1.11 - History of vascular endothelial growth factor and retinal disease 
 
In 1971, Folkman proposed the use of an anti-angiogenic agent to treat ophthalmic 
disease. (89) One therapeutic target molecule identified was VEGF (a dimeric 
glycoprotein of approximately 40kDa) (90), which had been associated with 
ischemia, as evidenced by its presence in hypoxic tumours throughout the body.  Its 
role in mediating neovascularisation in ischemic retinal disorders (diabetic 
retinopathy and retinal vein occlusions) was demonstrated by Aiello and Adamis in 
1994. (91, 92)  It has also been implicated in the pathogenesis of retinopathy of 
prematurity, (93) sickle cell retinopathy, in addition to a secondary role in 
neovascular glaucoma (94) and inherited retinal dystrophies. (95) In these 
conditions, the primary stimulus for VEGF up-regulation is reduced oxygen partial 
pressure, leading to hypoxia in retinal pigment epithelial cells and retinal pericytes 
(92) resulting in activation of hypoxia inducible factor 1α. (96) This process is unlike 
nAMD, where the contributing events leading to VEGF up regulation appear to be 
multifactorial.    
Around the same time period, VEGF-A (one of seven VEGF proteins found in 
mammals along with VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and placental 
growth factor (PGF) (90) was identified as having a central role in angiogenesis by 
several investigators including Folkman in the field of oncology. (97) VEGF-A has at 
least 9 isoforms, with VEGF-A165 being the most common isoform expressed.    
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1.11.1 Role of vascular endothelial growth factor - physiological 
Multiple cells located in the retina produce VEGF, including RPE, vascular 
endothelial cells, pericytes, Muller cells and astrocytes.  This suggests that VEGF 
plays an important role in ocular homeostasis. (98) Vascular endothelial growth 
factor has been shown to support neuronal and endothelial cell integrity in the mature 
retina, (99) leading to endothelial cell survival. (100) Evidence has also shown VEGF 
signalling plays a key role in maintaining RPE, Bruch’s membrane and choroidal 
endothelial cells. (90) Therefore, there is concern surrounding its complete inhibition, 
where its supportive function could be important in slowing down visual loss resulting 
from the GA phenotype of macular degeneration. (90) 
Vascular endothelial growth factor receptors have also been localised to retinal 
neurons, supporting its role in maintaining neuronal health. (101) (102) Mice 
rendered unable to express VEGF in the setting of hypoxia developed a motor 
neuron disease, (103) further adding to concerns of secondary neuronal damage 
related to VEGF inhibition. (90) 
 
1.11.2 - Role of vascular endothelial growth factor - pathological 
Vascular endothelial growth factor is a potent, endothelial cell mitogen, which 
promotes endothelial cells growth and survival. (90) It is responsible for increased 
vascular permeability (partially through promoting a fenestrated phenotype) (104) 
and promoting neovascularisation. Increased VEGF production results from oxidative 
cell stress, and is usually an effective defensive response of the body to cause 
proliferation of new blood vessels and a neovascular membrane.  These newly 
formed vessels are immature and leak blood and exudate, damaging surrounding 
retinal tissues, especially photoreceptors. (79) Clinicopathological studies in humans 
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have shown increased VEGF-A levels in both the vitreous and excised CNV 
membranes of patients with nAMD. (105, 106) 
Following these discoveries involving VEGF, agents designed to block this protein 
were developed. The first of these anti-VEGF agents was bevacizumab (Avastin, 
Genentech) a monoclonal antibody approved for oncological treatment in the United 
States of America (USA) in 2004 that was adopted for use in the eye.  This drug, 
along with others with a similar mechanism of action (pegaptanib, ranibizumab) binds 
to endogenous VEGF, hence inactivating the molecule, reducing angiogenesis, and 
at the time represented the latest revolution in treatment options for AMD. Vascular 
endothelial growth factor’s pathological role was supported by surgically obtained 
CNVM specimens in patients with AMD, which showed the presence of VEGF-A, 
leading it to be one of the current major target molecules of therapies for nAMD.  
(107-109)  
Despite identifying VEGF as an end-stage mediator of CNV, a thorough 
understanding of the primary trigger for nAMD remains incomplete.  One proposed 
theory is that the formation of CNV in nAMD is a secondary reaction to a pathological 
process that occurred earlier in life. This process may have led to RPE damage, 
evoking an immune response involving the production of pro-angiogenic factors, 
upsetting the equilibrium between pro-angiogenic and anti-angiogenic cytokines, 
thereby promoting CNV. (110)
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1.12 Anti-vascular endothelial growth factor agents 
 
Treatment of nAMD has undergone a revolutionary change in the last decade (since 
2007) with the standard of care currently being intravitreal anti-VEGF. Each anti-
VEGF agent exhibits variations in its exact targets, however their therapeutic 
endpoint is in reducing the effect of VEGF.  Anti-VEGF agents are the first type of 
treatment that has resulted in the improvement of vision in a large proportion of 
patients. (18)  
The goal of inhibiting VEGF-A is to reduce intra and sub-retinal oedema, by reducing 
vascular permeability.  Anti-VEGF agents can also lead to regression of the 
neovascular membrane, and should this occur, it is thought to increase the duration 
of treatment effect. (111) However, improvement of visual function has been found in 
cases with oedema control without regression of the CNV membrane (MARINA trial), 
implying that the major driver of visual improvement is the reduction of retinal 
oedema. (112) 
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1.12.1 - Pegaptanib 
Pegaptanib (Macugen, Eyetech Pharmaceuticals, Pfizer Inc, New York) was the first 
VEGF inhibitor developed for the eye, and approved by the Food and Drug 
administration (FDA) of the USA for use in nAMD in December 2004. Unlike 
ranibizumab, it binds and inactivates only one isoform of VEGF-A (VEGF-A 165).  
At 12-months, 70% (206/294) of patients with predominantly “classic” CNV treated 
with 0.3mg of pegaptanib had stable vision (lost <15 letters) compared with 55% 
(164/296) of controls treated with sham injections. (p<0.001) (113) This outcome was 
favourable when compared to PDT.  
At 12-months, 6% of patients treated with 0.3mg had an improvement of >15 letters 
of VA. This rate was far lower than the ANCHOR and MARINA clinical trial cohorts, 
who were treated with ranibizumab. 
During the clinical trials for pegaptanib, concerns were raised surrounding ocular 
adverse events.  There was a 1% endophthalmitis rate, along with similar rates of 
other serious ocular adverse events including retinal detachments and traumatic 
cataracts. It is plausible that these events were related to the learning curve 
surrounding the administration of regular intravitreal injections to large numbers of 
patients, which at the time was a new practice. (113) 
Pegaptanib was not marketed in Australia; hence few patients in this country had 
access to this treatment apart from those enrolled in clinical trials.   In the USA, some 
early nAMD cases treated with ranibizumab were found to have better outcomes 
compared to pegaptanib, (79) and consequently it was less used when other anti-
VEGF therapies became available. Pegaptanib is no longer recommended as a 
treatment for nAMD. 
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1.12.2 - Bevacizumab 
Bevacizumab (Avastin, Genentech, San Francisco, California) is a humanised, 
monoclonal full-length immunoglobulin G (IgG) antibody against VEGF that inhibits 
the normal function of VEGF-A by binding to all of its isoforms. (114) This was initially 
developed as an oncology medication, to inhibit pathological angiogenesis in 
tumours and was in clinical use by 1997. (115) Once approval was given to treat 
metastatic colorectal cancer by the FDA, its off-label use for ocular conditions, 
especially nAMD became widespread. Bevacizumab was first reported to be effective 
for treating nAMD in 2005. (116) It shares the same murine antibody as ranibizumab. 
(79) Its major structural difference is a larger molecular size at 149-kD, vs. the Fab 
fragment of ranibizumab at 48kD.  This difference results in a longer half-life 
compared with ranibizumab and likely explains reports of bevacizumab remaining 
detectable in second eyes after injection, unlike ranibizumab. (117) 
Another major difference is its low price at approximately one-fortieth the cost of 
ranibizumab and aflibercept.  Recent head to head studies have demonstrated non-
inferiority of bevacizumab when compared to ranibizumab in most treatment regimes. 
(118, 119)  
One of the major concerns of using bevacizumab has been the increased risk of 
cardiovascular events, stroke and gastrointestinal bleeding. These adverse events 
have been reported in patients undergoing systemic treatment for oncological 
indications, (120) and supported by laboratory evidence of the molecule having a 
prolonged half-life in the systemic circulation. (116-120) The potential safety issues 
are discussed in Chapter 1.14.  
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1.12.3 - Ranibizumab 
Ranibizumab (Lucentis, Genentech Inc., South San Francisco, CA) was designed as 
a competitive VEGF inhibitor, originating from murine species. The antibody was 
available for use in Australian from 2007, and it was the first nAMD treatment that 
reversed visual loss in a large proportion of patients.   
Ranibizumab is a fragment of recombinant, humanised monoclonal antibody 
targeting multiple isoforms of VEGF-A (VEGF110, VEGF121, VEGF145 VEGF165 
VEGF183, VEGF189, VEGF206). These isoforms usually bind to VEGF receptors on 
the cell surfaces of endothelial and mural cells, leading to endothelial cell 
proliferation, neovascularisation and increased vascular permeability via a tyrosine 
kinase-signalling pathway. (79) The absence of the fragment crystallisable (Fc) 
portion of the AB contributes to its molecular weight of 48kDa, (121) which is smaller 
than bevacizumab and has been shown to penetrate the retina well. (122) The 
absence of the Fc portion also removes the possibility of activation of the innate 
immune system, (123) and leads to rapid systemic clearance, (124) both of which 
theoretically reducing the risk of systemic adverse events compared to bevacizumab.  
It provided a substantial benefit over the 1st generation anti-VEGF treatment 
introduced in 2004 (pegaptanib) in that it improved or stabilised vision in 90% of 
patients at 12-months vs. 70% in the pegaptanib arm. (113) Additionally, it proved its 
effectiveness targeting angiographically classic, occult or mixed lesions unlike PDT, 
which was only proven to be effective for predominantly classic lesions (a small 
proportion of nAMD cases). 
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1.12.3.1 – The evolution of ranibizumab treatment regimes 
Since ranibizumab was introduced in Australia in 2007, several studies have 
influenced the pattern of treatment, specifically impacting on the frequency of 
injections, and the methods used to determine retreatment.  
 
1.12.3.1.1 - Establishing a clear benefit for ranibizumab 
Landmark clinical trials that shifted the paradigm of nAMD treatment towards anti-
VEGF agents, and specifically ranibizumab, were the MARINA, (17) and ANCHOR 
(18) studies.  In MARINA and ANCHOR, 90% of patients achieved VA stability (lost 
fewer than 15 letters) at 24 months. VA gains of 15 or more letters were seen in 33% 
to 41%. (17, 18) Patients in the treatment arm of the ANCHOR study had a lower 
rate of legal blindness at the end of the trial (12% vs. 43% of patients in the sham 
injection group). Therefore head to head studies of ranibizumab against PDT 
(standard of care for occult lesions at the time of the MARINA study) and sham 
injections (ANCHOR study) showed that ranibizumab led to superior visual 
outcomes.  Furthermore, the angiographically visible area of CNV lesion showed no 
significant change over 1 year in the MARINA study, compared with a 2 disc 
diameter increase in the size in the control group, indicating that ranibizumab 
arrested the growth of CNVM without leading to immediate regression of the lesion.   
A monthly treatment regime was utilised for these studies, which placed great 
burdens on the patients, their carers, and the health systems, in addition to regularly 
exposing patients to the adverse events associated with an intravitreal injection 
(Chapter 1.14). Therefore, monthly treatment may be impractical in routine clinical 
practice and alternative strategies were investigated.  Subsequent treatment trials 
aimed to reduce this burden of treatment by reducing the frequency of injections.  
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1.12.3.1.2 - An effective treatment regime with less frequent injections 
The Phase IIIb, Multicentre, Randomised, Double‐ Masked, Sham Injection‐
Controlled Study of the Efficacy and Safety of Ranibizumab (PIER) (125, 126) 
assessed the efficacy of 0.3mg and 0.5mg dosing on patients with nAMD with classic 
or non-classic angiographic appearance.  It was one of the first trials attempting to 
establish an effective regime with a fixed treatment interval greater than 1 month.  
Patients were injected with a monthly loading dose over 3 months, followed by 
reinjections every 3 months. These patients were found to have an improvement 
compared to sham injections, however the results were inferior to the MARINA and 
ANCHOR trials. The Efficacy and Safety of Ranibizumab in Patients With Subfoveal 
CNV Secondary to ARMD (EXCITE) study also assess the role of quarterly vs. 
monthly injections, with results consistent with the PIER study findings. (127) 
Secondly, in the PIER study VA was found to improve once patients were switched 
from quarterly dosing to monthly dosing, (126) indicating that more frequent 
administration was linked to better outcomes. The HORIZON study found a similar 
outcome from the opposite perspective, in that switching patients from a monthly 
schedule to a less frequent, investigator determined as-needed dosing (pro re nata, 
(PRN)) resulted in poorer visual outcomes. (128)  
The PIER study also established that there was no difference in the proportion of 
patients who improved their VA >15 letters when administered 0.3 vs. 0.5mg of 
ranibizumab.  This finding helped established the accepted dose of 0.3mg via 
intravitreal injection. Furthermore, PIER found that patients who were switched from 
the sham injection arm for 1 year to the treatment arm continued to experience a 
decline in their vision. This suggests the importance for early treatment of nAMD 
lesions would result in superior outcomes. 
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1.12.3.1.3 - Incorporating clinical indicators for re-treatment 
The Prospective OCT imaging of Patients with Neovascular AMD Treated with Intra-
Ocular Lucentis (PrONTO) study aimed to reduce the burden of injections by using a 
clinical algorithm to guide retreatment on a PRN basis with monthly visits irrespective 
of the clinical findings in the previous month. (129) This algorithm included VA, OCT, 
fundus, and FFA features.  The criteria for retreatment was as follows: 
Any one of the following when compared with the previous month’s data: 
1. At least 5 letters VA loss with OCT evidence of fluid at the macula 
2. Increase in OCT central thickness of at least 100um 
3. New macular haemorrhage (clinical exam or photographic) 
4. New area of classic choroidal neovascularization on FFA 
5. Persistent fluid on OCT 1 month following a previous injection.  
The PrONTO study protocol mandated the established loading dose of 3 monthly 
injections prior to application of its clinical algorithm for retreatment. The 24-month 
results showed average VA gains of 11.1 letters comparable with the MARINA and 
ANCHOR trials, with a much-reduced number of injections of 9.9 injections over 24 
months.  This compared favourably with the MARINA and ANCHOR trials, which 
required 24 injections over 24 months. (129) Although the sample size was small 
(n=40) it helped shift the paradigm surrounding injection frequency, indicating that 
not all patients required monthly injection to achieve an optimal outcome, and that 
the use of additional clinical indicators was helpful.  Whilst the injection frequency 
was reduced, (and therefore the risks and costs associated with injection also 
reduced), burdensome monthly visits were still required in this protocol. 
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The criteria for retreatment incorporating OCT features in the PrONTO study was an 
evolutionary step towards further PRN protocols used in subsequent studies, in 
addition to the current most practiced treatment regime in Australia, treat and extend 
(TaE). 
In the large, multicenter CATT (Comparison of Age-Related Macular Degeneration 
Treatments Trials), the efficacies of ranibizumab and bevacizumab were compared 
to each other, and different treatment regimes within each drug were compared 
(OCT-guided PRN dosing vs. fixed monthly retreatment strategies over 2 years). 
Although fixed monthly retreatment led to greater mean visual acuity gain, the VA 
differences between PRN (+8.8 letters) and monthly (+6.7 letters) groups were 
considered as not significantly different for the ranibizumab groups (according to the 
non-inferiorly margin predefined as 5 letters). (118) When PRN patients of both drugs 
were compared to monthly treated patients of both drugs, there was a 2.4 letter 
superior outcome in mean VA with ranibizumab. Bevacizumab and Ranibizumab 
were found to have equivalent visual outcomes at 2 years when used with the same 
dosing regime, with the visual gains within 1.4 letters of each other between drugs. 
The greatest difference in mean VA gain was between ranibizumab monthly and 
bevacizumab PRN (3.8 letters).  
The CATT suggested inferior anatomical outcomes with bevacizumab, which had an 
OCT fluid free status of 13.9% and 22.3% for PRN and monthly regimes vs. 30.2% 
and 45.5% for the corresponding ranibizumab groups.  The resolution of fluid as a 
treatment outcome, and its effect on visual function is the subject of recent clinical 
trials. (130)  
The Phase III, double-masked, multicenter, randomised, active treatment-controlled 
study of the efﬁcacy and safety of 0.5 mg and 2.0 mg Ranibizumab administered 
monthly or on a PRN basis in patients with subfoveal neovascular age-related 
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macular degeneration (HARBOR) comparing monthly ranibizumab to a PRN regime 
over 2 years. (131) Mean visual acuity was +9.1 letters compared to baseline in the 
monthly 0.5mg group compared to +7.9 letters in the 0.5mg PRN group. Of note, the 
number of injections in the PRN arm was 13.3 over 2 years, with 5.6 injections in 
year 2. The PRN group did not meet the pre-determined non-inferiorly margin of 4 
letters, therefore PRN dosing was not considered to be equivalent to monthly dosing, 
although a meaningful clinical improvement was achieved in both groups. This is 
despite similar mean 1-year VA results to the equivalent arm of the CATT at 1 year, 
which had a different non-inferiorly margin of 5-letters, and concluded that PRN 
dosing was non-inferior to a monthly regime. (132) 
Within the HARBOR study, there was a large variation in the number of injections 
required in their PRN treatment group was reported (3 – 24 injections over 2 years).  
This suggests that some patients will be under or over treated if a fixed treatment 
regime was adopted. There are few baseline markers that predict the frequency of 
injections required over 5-years of treatment. 
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1.12.3.1.4 - Treat and extend regime  
Treat and extend involves fixed treatment intervals until clinical remission, (as 
determined by OCT and other clinical findings similar to the PrONTO protocol) 
followed by an increasing treatment/review interval.  There are several variations of 
this treatment protocol, with one common regime involving reviews and injections 
progressively extending by 2 weekly intervals if there are no signs of disease activity, 
until a maximum of 3 months.  If there are markers of disease activity, the treatment 
interval is reduced by 2 weeks.  
Scarce data is available about the outcomes of this treatment regime. The first 
prospective study of a 12-month TaE regime was published in 2013 by Toalster et.al. 
(133) They reported a mean VA improving from Snellen 20/62 at baseline to 20/46 at 
12-months with a mean of 8 injections per patient. Abedi et al. (134) conducted a 2-
year prospective study, and reported an improvement of +9.5 letters at 12-months 
(Mean injections 8.6) and 8.0 letters at 24-months (mean injections 5.6 in year 2).  In 
both of these studies, a dry macula was required before extension (defined as an 
absence of fluid on OCT or haemorrhage). Both prospective TaE studies provided 
encouraging data to suggest that such a regime can produce clinically meaningful 
outcomes, whilst markedly reducing the injection burden.  Prospective studies 
comparing an TaE protocol with a PRN protocol are lacking, but would further clarify 
the best flexible treatment regime. If TaE is found to be non-inferior to PRN, resulting 
in a shift of all patients to TaE, it would markedly reduce the number of visits required 
for patients, whilst maintaining the flexibility of treating patients according to the large 
variation in numbers of injections required.  
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1.12.4 - Aflibercept 
Aflibercept (Eylea, Regeneron, Tarrytown, NY) differs from other anti-VEGF agents 
in its mechanism of action, as it is a VEGF receptor fusion molecule that binds to the 
VEGF ligand (with a higher affinity than the native VEGF receptor). Its binding affinity 
is higher than ranibizumab and bevacizumab. (135) It also binds PGF, which is 
present on endothelial cells and leucocytes. (135) Its arrival initially brought hope for 
a drug that would decrease the injection burden for many patients compared to the 
established agents at the time (ranibizumab and bevacizumab).   
The phase 3 VEGF trap-eye: Investigation of efficacy and safety in wet AMD study 
(VIEW)-1 and VIEW-2 studies (136) were the landmark trials assessing efficacy of 
aflibercept vs. ranibizumab. The treatment arms were aflibercept 0.5mg monthly, 
aflibercept 2.0mg monthly, aflibercept 2.0mg every 2-months following 3 initial 
monthly doses, and 0.5mg ranibizumab monthly.  Findings from baseline to 52 
weeks were that that 2-monthly 2mg aflibercept was not-inferior to monthly 0.5mg 
ranibizumab (control arm).  The non-inferiorly criterion applied to the study was the 
proportion of patients maintaining their visual acuity having less that 10% variance.  
Between 52 and 96 weeks, the treatment interval for all 4 treatment arms was 
changed to PRN dosing.   For weeks 52 – 96, an average of 4.2 injections were 
required for 2.0mg aflibercept and 4.7 injections for 0.5mg ranibizumab during the 
second year of the study. Visual acuity results were considered to be equivalent 
between these 2 arms, although there was a slight reduction in the mean VA of all 
arms. It is noteworthy that the injection interval during the second year of the study 
was capped at 12 weeks irrespective of disease inactivity, suggesting that the 
treatment interval could have been extended further for both ranibizumab and 
aflibercept. The driver behind the higher number of average injections in ranibizumab 
was a higher proportion of these patients that required intensive treatment, 
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suggesting that those with greater disease activity may require fewer injections with 
aflibercept. (137) 
Aflibercept has been shown to have a role in nAMD patients resistant to treatment 
with regular ranibizumab therapy.  Chang et.al published a prospective study with 49 
treatment resistant patients switched to aflibercept. They found a 4.7 letter 
improvement along with a 97.2um reduction of central retinal thickness at 12-months 
compared to baseline. (138) 
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1.12.5 – Continuing challenges of anti-VEGF therapy 
Despite the significant progress made in the age of anti-VEGF agents, it is not a 
panacea for nAMD.  A sizeable proportion of patients are non-responders, whilst 
others suffer a recurrence should treatment cease, often in an unpredictable fashion. 
(139) Regular visits to an eye clinic are mandated, and treatment may be lifelong 
which results in an extremely burdensome exercise for the patient and their families. 
There are still a lack of reliable baseline biomarkers for nAMD recurrence, and long-
term prognosis, which would allow more individualised therapy (140) and aid in the 
counselling of patients. A treatment modality to prevent CNV formation has not been 
developed to date, which would represent the ultimate remedy for nAMD’s potentially 
blinding outcomes.  
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1.13 - Safety concerns of anti-vascular endothelial growth factor agents 
and its administration 
There are safety concerns related to the ocular and systemic consequences of 
inhibiting VEGF by agents such as ranibizumab. Secondly, there are concerns 
surrounding adverse events related to administration of intravitreal injections. 
1.13.1 – Anti-vascular endothelial growth factor crossing into the systemic 
circulation, and the differences between ranibizumab and bevacizumab:  
Bakri et.al (117) demonstrated in an animal model that 1.6% of the injected 
bevacizumab dose crossed into the systemic circulation. In 2009, Rosenfeld at 
Bascom Palmer Eye Institute reported a treatment effect on nAMD from systemically 
administered bevacizumab.  This demonstrated that bevacizumab could cross from 
the systemic circulation to the ocular circulation, validating concerns that systemic 
absorption of the drug may lead to drug-mediated systemic adverse events. (141) 
This issue is also thought to be relevant for ranibizumab, although caution should be 
exercised in extrapolating safety data of one anti-VEGF agent to another due to 
biochemical differences in the agents and their effects at the molecular level. (142)  
Accepting that these intra-vitreal agents can cross into the systemic circulation, and 
that bevacizumab has a longer half-life than ranibizumab(143), it remains unclear 
whether this intra-ocular concentration is sufficient to mediate a systemic adverse 
event, and whether there is a difference between these agents. Several recent 
randomised control head to head trials between bevacizumab and ranibizumab have 
demonstrated a statistically significant increase in adverse events over baseline with 
either agent, without a difference between drugs. (118, 119)  The lack of difference 
between drugs is also supported by long-term surveillance studies of patients 
continuing treatment after clinical trials such as the HORIZON study (an open label 
extension trial of patients treated with ranibizumab in the ANCHOR, MARINA and 
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FOCUS studies), which showed no increased rate of adverse events compared with 
baseline rates. (128) The CATT study did however note an increased risk of serious 
adverse events with bevacizumab (relative risk (RR) 1.29 compared to ranibizumab).  
It is critical to note that the CATT was not statistically powered to assess differences 
in safety.   Since the CATT was completed, there have been several other 
randomised controlled trials comparing ranibizumab with bevacizumab. A Cochrane 
review did not find a difference in serious systemic adverse events between these 
anti-VEGF agents. (144) 
1.13.2 - Systemic adverse events related to ranibizumab 
All anti-VEGF therapies carry a theoretical risk for systemic thromboembolic events. 
The antiplatelet Trialists’ Collaboration defines these to include haemorrhagic and 
ischemic cerebrovascular conditions, myocardial infarction. In HORIZON and 
SECURE studies (both open label extension trials of ranibizumab), the proportion of 
patients with these systemic events was 5.6% and 5.3% over 4 years.  
Vascular endothelial growth factor has a physiological role in vascular homeostasis 
via mediation of nitric oxide causing vasodilation of vessels, and by promoting 
neovascularisation.  Vascular endothelial growth factor blockade can therefore 
increase blood pressure. (145) In the HORIZON and SECURE studies, hypertension 
affected 8.7% and 9.0% of the study populations respectively. (128) (146)
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1.13.3 - Ocular adverse events 
The SAILOR study (147) is one of the largest Phase III studies to assess the 
incidence of adverse events (AE) with ranibizumab therapy over 12-months, with a 
total cohort of 4300 patients.  With regards to serious adverse events, rates quoted 
were traumatic cataract (0.08%), retinal detachment (0.1%), retinal tear (0.1%), 
endophthalmitis (0.2% - 0.4%, both cases were presumed with no organism isolated) 
vitreous haemorrhage (0.9%), and ocular inflammation (1.0% - 1.5%, all figures 
expressed as a % of all patients).  Interestingly the study did not report the rate of 
IOP elevation, a recognised adverse event from intravitreal injections.  
The LUMINOUS study was post-marketing surveillance research that collected 
safety data from patients treated with ranibizumab in the real-world clinical setting. 
This study included 4444 patients, with the serious ocular events included RPE tear 
(0.61% of patients), intra-ocular pressure events (0.27%) and traumatic cataract 
(0.23%). (148) 
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1.13.4 - Measures to decrease the incidence of endophthalmitis 
The use of antibiotics pre-injection, immediately after injection and in the days after 
injection has not been shown to reduce the risk of infection. (149) Some studies have 
shown that the routine use of prophylactic antibiotics can promote antibiotic 
resistance and increase the risk of endophthalmitis. (150) 
An expert panel recommends povidine-iodine use. There are no controlled trials 
comparing endophthalmitis rates between patients with and without povidine iodine, 
however the evidence base cited draws on data from cataract surgery with and 
without povidine iodine. In these cataract studies, the use of povidine – iodine was 
associated with a reduction of infection risk. (149)   
Eye speculums or manual retraction of the eyelids are recommended for intravitreal 
injections. There is no evidence that a speculum is superior to manual retraction. 
(151) The main goal is to prevent contact of the eyelash/eyelid margin with the 
injection needle to prevent the intraocular introduction of commensal organisms 
The use of facemasks for the injecting physician may reduce the risk of 
endophthalmitis. An in vitro study by Wen et.al (152) investigated the rate of bacteria 
grown on culture media when subjected to a volunteer speaking with and without a 
face mask for 5 minutes, and standing in silence for 5 minutes.  Significantly greater 
amounts of streptococcal species were grown in the agar plates exposed to 5 
minutes of talking without a facemask. (152) Turning the face whilst speaking did not 
significantly reduce the risk of this growth, and therefore the recommendation from 
this study is for injecting personnel to wear a face mask, and to ask the patient to 
minimise talking during the procedure.
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1.14 - Long – term outcomes of ranibizumab therapy 
At the time of the LTRS design, there was limited long-term data on outcomes 
following ranibizumab treatment for AMD, in a non-trial clinical setting, with disease 
activity guided retreatment. The HORIZON extension study published by Singer in 
2012 reported 60 month adverse events outcomes from 73 patients who were 
formerly enrolled in the ranibizumab treatment arms, and 43 patients previously 
enrolled in the control arms of three randomised controlled trails, (MARINA, 
ANCHOR, FOCUS.) (128) Given that these patients started treatment whilst on a 
clinical trial, with fixed, monthly treatment protocols for the first 24 months, the 
HORIZON extension results outcomes would not reflect the majority of real world 
clinical practice, where both frequency of injections and number of follow-up visits 
were far less than 12 per year in the first 2 years following diagnosis.  
Clinical studies that had reported long-term (4-year) visual outcomes had small 
numbers based on a “survival analysis” method of analysis. In 2013, Fauk et.al. 
reported 7 patients with data for 48 months (153), and in 2012 Pushpoth et.al. 
reported results from 110 patients with 48 months of follow-up, of which 97 had 48-
month vision data (approximately 10% of the original treated cohort). (154) Pushpoth 
found stable vision in 82% of patients at 4-years (defined as not losing >15 letters 
compared to baseline).
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 1.15 - Other issues surrounding management of neovascular age-
related macular degeneration with anti-vascular endothelial growth 
factor agents 
 1.15.1 - Does anti-vascular endothelial growth factor treatment in the first eye 
result in a benefit to the second eye? 
There is a notion that anti-VEGF agents administered by the intra-vitreal route of one 
eye can cross into the second eye via the systemic circulation, and therefore exert a 
prophylactic or therapeutic effect on diseases that are mediated by this molecule, 
including proliferative diabetic retinopathy and nAMD. There are several reports that 
support this hypothesis. (117, 155-157)  
Avery reported 2 cases of proliferative diabetic retinopathy (PDR) that following 
injection with 1.25mg of intravitreal bevacizumab showed a reduction of fluorescein 
leakage in the second eye. This suggests that the second eye may receive some 
benefit from the anti-VEGF agent from the injected eye. (155) These findings also 
support the concerns surrounding the systemic toxicity and consequent 
cardiovascular adverse events following an intravitreal injection of anti-VEGF agent.  
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Bakri in 2007 studied the vitreous half-life of 0.5mg ranibizumab and 1.25mg of 
bevacizumab administered by intravitreal injection into a rabbit model. (117) The half-
life was 2.88 days for ranibizumab vs. 4.32 days for bevacizumab.  In this study, 
ranibizumab was not detected in the serum or second eye, whereas bevacizumab 
was detected in serum and the second eye, peaking in concentration between the 5th 
and 10th day following injection. In contrast, other clinical reports have suggested the 
lack of a second eye effect including Velez-Montoya et.al (141) who found no 
observable clinical effect in the second eyes of patient injected with bevacizumab for 
diabetic macular oedema (DMO) The authors did acknowledge that a limitation of 
their study was the small sample size. A retrospective analysis of ranibizumab in 
MARINA and ANCHOR trials did not show a statistically significant difference in the 
incidence of second eye nAMD between the treatment arms and the control arms, 
suggesting that there was minimal protective effect exerted on the second eye, (PDT 
and placebo respectively) (42) It therefore remains unclear whether second eyes 
received a clinically meaningful benefit from anti-VEGF agent  
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1.15.2 - The rate of recurrence of inactive disease 
There is limited data on the rate of recurrence of a ranibizumab treated, inactive CNV 
lesion.  Rasmussen reported that of 120 eyes that had ceased treatment over 4 
years as a result of clinically inactive disease, 25 (20.1%) were subsequently referred 
for further treatment. (158) Vuze et.al reported a recurrence rate of 91% for nAMD in 
patients who had ceased intravitreal bevacizumab or ranibizumab for more than 3 
months.  In this cohort of 103 patients, the mean follow up period was 33.1 weeks, 
and no correlation was found with the size or angiographic type of the initial lesion. 
(159) Currently it is unknown how frequently a patient should be re-examined after 
apparent disease inactivity. 
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1.16 - Anti vascular endothelial growth factor agents - economic 
considerations 
 
1.16.1 - Direct costs to the health system 
As of August 2007, ranibizumab has been funded by the Australian government 
through the PBS, at a cost of $1976 Australian dollars (AUD) per injection, lowering 
to $AUD1431 on 1 April 2013. (Drug utilisation sub-committee - ARMD utilisation 
analysis, June 2015)  By 2010, ranibizumab was the second highest costing drug on 
the Australian Pharmaceutical Benefits Scheme at $237 million. Totalling $AUD 
173.7 million in the 2014 financial year in drug costs alone, (160) ranibizumab is 
currently the eighth most costly drug on the Australian PBS and combined with 
aflibercept  ($AUD 181.6 million in 2014  forms the second most expensive class of 
medication on the PBS after the lipid modifying medications atorvastatin and 
rosuvastatin. (160) In 2014, 249,722 approved anti-VEGF injections were 
administered in Australia for nAMD in 2014 and this figure has been increasing since 
2007. (160) There are significant additional costs to the health care system related to 
the administration of these injections, and the clinic based investigations and reviews 
necessary to guide ongoing treatment.  
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1.16.2 - Neovascular age-related macular degeneration related legal blindness 
The nAMD phenotype of AMD is a disease with significant social burden.  Two-thirds 
of all cases of late AMD are neovascular, and visual loss often occurs over months, 
in contrast to the other subtype of late AMD (geographic atrophy) where loss occurs 
more gradually over decades.  A recent analysis of the effect of ranibizumab 
treatment in Australia found that over a 2-year period, treatment reduced the rate of 
legal blindness (Snellen VA >6/60) by 68%, (1622 cases) and visual impairment 
(Snellen VA <6/12) by 28% (1774 cases). (6) These results were consistent with 
findings of a real-world database from Denmark, which found a relative risk reduction 
of 50% for nAMD related blindness over the 5-years following the introduction of 
nAMD, compared with the preceding 5-years. (161) Although the Australian results 
were based on statistical modelling, and did not incorporate an economic cost/benefit 
analysis for Australia, it is compelling data that suggests a net economic gain for 
society, in addition to a functional benefit for the patient.  One American analysis 
estimated the cost/benefit ratio for ranibizumab at $63300 United States Dollars 
(USD) per quality adjusted life year (QALY) for monthly dosing and $USD18600 for 
PRN dosing. (162) This was contrasted with the cost of bevacizumab at 
$USD2676/QALY for monthly dosing and $USD3333/QALY for PRN dosing. 
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1.16 3 - Worldwide access to ranibizumab  
As of May 2012, ranibizumab (Lucentis) was fully funded by governments of a limited 
number of countries (US, Australia, UK, France, Germany, Japan, Brazil, 
Switzerland, Austria, Sweden (Novartis Pharmaceuticals, Australia, May 2012).  At 
approximately AUD$2000 drug cost per injection in 2012, there was a wide cost gap 
between this medication and its alternative bevacizumab (Avastin, approximate cost 
$50 per injection) used in many other countries.  This highlights that many countries 
are unable, or unwilling to fund the cost of ranibizumab whilst an alternative is 
available. 
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1.17 - Unresolved questions in neovascular age-related macular 
degeneration management and thesis hypothesis 
 
There are few real world studies on the long-term treatment of nAMD. Whilst it is 
clear that ranibizumab is an effective treatment under trial conditions, its efficacy 
when administered under real-world conditions is unclear.  There is a movement 
towards administering less injections, however the evidence suggests that this 
results in inferior outcomes compared to monthly injections.(128) The proportion of 
patients that still require regular treatments over 5-years in the real world is also 
unknown. It is assumed that there would be value for continuing monitoring and 
treatment during the 5-year period. This study hypothesised that ranibizumab would 
have long-term benefit in maintaining the VA and anatomical structure in patients 
with nAMD using an individualised treatment regime whilst reducing the burden of 
injections.  
The long-term safety of ranibizumab injections is unclear, with some studies 
suggesting a high endophthalmitis rate. This study hypothesised that safety profiles 
recorded from long-term ranibizumab treatment in real-world setting may be more 
representative of routine clinical practice compared to the short-term clinical trials.   
The natural history of nAMD without treatment leads to rapid visual decline, and 
intuitively it would seem that early treatment would result in superior outcomes, 
supported by studies that showed good baseline visual acuity is a positive baseline 
prognostic sign for final visual outcomes.(140) The rate of second eye involvement is 
high, and with the advent of anti-VEGF therapy and regular treatment regimes, there 
is now an opportunity to regularly examine the second eye.  It is unclear how often 
patients are symptomatic, or are shown to have a decrease in VA, whilst there is a 
sub-foveal CNVM visible on FFA.  It is also unclear whether treating these early 
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lesions (that may be asymptomatic and have minimal impact on VA) would be 
beneficial. The second eye ranibizumab study (SERS) hypothesised that closely 
monitoring second eyes of the patients whose first eye is undergoing ranibizumab 
treatment will be effective in early detection and treatment of nAMD in the second 
eye. This is thought that second eyes would show better VA and anatomic structure 
findings at 1-year compared to the first eye. 
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1.18 - Thesis aims 
The first aim is to evaluate the long-term visual and anatomical of intravitreal 
ranibizumab (an anti-VEGF agent) in treating nAMD by examining a cohort over 5-
years within a real-world clinic setting. Furthermore, the long-term pattern and safety 
of ranibizumab injections for treating nAMD will be assessed. 
The second aim is to compare the clinical presentation and treatment outcomes 
between the first and second treated eyes in patients that developed nAMD in both 
eyes whilst under regular clinic follow-up. 
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CHAPTER TWO – General methods for studies 
2.1 - Introduction 
This chapter outlines the methodology used to establish the overall ranibizumab 
retrospective database, clinic follow-up protocol and assessment of patient outcomes 
relevant to all arms of the thesis.  Methodologies specific to the individual studies will 
be included in the relevant chapters. 
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2.2 - Patient recruitment 
Sydney Retina Clinic (SRC) is a tertiary ophthalmic referral centre, primarily treating 
vitreo-macular disease.  Patient assessment, investigations and treatment are 
carried out onsite in combined clinic rooms and day procedure unit. 
Patients are referred by public hospital ophthalmology clinics, ophthalmologists in 
private practice, optometrists and general practitioners. 
This study adhered to the tenets of the Declaration of Helsinki, and ethics approval 
was obtained from Human Research Ethics Committee, The University of Sydney. 
Informed consent was obtained from all participants before they were recruited into 
the study. 
2.2.1 - Study design and establishment of the database: 
The ranibizumab retrospective database was designed with two major aims:  
1) To investigate the long-term (5-year) outcomes of nAMD treated with 
ranibizumab in a clinical setting (LTRS). 
2) To investigate the clinical presentation and outcomes of patients 
subsequently developing nAMD in the second eye whilst undergoing regular 
ranibizumab treatment for nAMD in the first eye (SERS). 
The study design for both LTRS and SERS was a retrospective, consecutive case 
series.  
2.2.2 - Eligibility for subsidised ranibizumab 
For eligibility for inclusion in the ranibizumab retrospective database, the patient 
needed to satisfy the criteria for government subsidy of nAMD treatment. In Australia, 
the PBS subsidises the use of ranibizumab for macular diseases. The criteria for 
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eligibility for subsidised ranibizumab treatment for nAMD (and therefore inclusion into 
the ranibizumab retrospective database) is as follows: 
1 - Age > 50 years old 
2 - sub-foveal CNV secondary to AMD diagnosed by FFA, with the lesion 
demonstrated on a retinal FFA 
Patients would also qualify for PDT (a therapy now considered second-line) if their 
pre-treatment VA is ≤6/60, and if their CNV appearance was predominantly (>50%) 
classic on FFA. All patients in this study received PBS subsidised ranibizumab, as 
this is available irrespective of the pre-treatment VA.  
2.2.3 – Inclusion and exclusion criteria 
Consecutive patients who commenced treatment with ranibizumab for CNV 
secondary to AMD between June 2007 - May 2008 were assessed for inclusion to 
the study. These patients underwent treatment by a single retinal specialist (AC) at a 
single practice (SRC). All ranibizumab vials were supplied by one pharmacy (Oze 
Pharmacy) who provided a complete record of every patient who had commenced 
treatment on ranibizumab and this formed the basis of the ranibizumab retrospective 
database. 
Inclusion criteria was nAMD diagnosed by fundus fluorescein angiography (FFA), 
commencement of intravitreal ranibizumab for nAMD between June 2007 and May 
2008 and completion of 5-years of follow-up from initial ranibizumab injection, with a 
single physician (AC) with no follow-up interval exceeding 6 months. June 2007 
coincided with the availability of ranibizumab though the Australian PBS.  
Each patient record satisfying the inclusion criteria between June 2007 - May 2008 
was accessed using practice management software VIP, (Houston Medical) and the 
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visits associated with a ranibizumab injection were identified.  The baseline (first) and 
last date of ranibizumab injections was identified, and the time interval calculated.  If 
this time interval was ≥5-years (60 months) for one eye (LTRS), or >12-months in 
each eye for those who had ranibizumab in both eyes (SERS) the patient satisfied 
the major inclusion criteria for the study database and a physical chart review was 
triggered for that patient.  
For patients with two eyes meeting the inclusion criteria for the LTRS, one eye was 
randomly selected using a computer randomiser to be included in the study.  
Patients were excluded from either the LTRS or SERS if the study eye underwent 
vitrectomy surgery at any time due to the increased clearance of intravitreal 
ranibizumab reported in animal models, (163) and reported clinically decreased 
efficacy of intravitreal bevacizumab in the treatment of diabetic macular oedema. 
(164). Additional exclusion criteria included treatment with PDT, intravitreal 
bevacizumab or triamcinolone during the follow-up period; or intravitreal ranibizumab 
prior to June 2007, and cataract surgery during the follow-up period.  
2.2.4 - Extension of the ranibizumab retrospective database for the second eye 
ranibizumab study (SERS) 
During preliminary analysis of the results for the LTRS, it was decided to expand the 
scope of the database to assess patients who developed nAMD in the second eye 
whilst being treated for nAMD in the first eye. All patients who commenced unilateral 
treatment with ranibizumab for nAMD at SRC between July 2007 and March 2012 
were assessed for inclusion, utilising dispensing data provided by OZE pharmacy. 
Patients who subsequently commenced ranibizumab treatment in their second eye, 
with at least 12-months of follow-up for both eyes at the end of the study duration, 
and treated by a single ophthalmologist (AC) were included in the study.  Exclusion 
criteria were applied as outlined in the previous section for the LTRS. 
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2.3 - Clinical protocols for the treatment of neovascular age-related 
macular degeneration 
2.3.1 - Baseline clinical assessment: 
“Baseline” is defined as the date of the nAMD diagnosis for patients recruited into the 
study.  At baseline, Snellen VA, intraocular pressure (IOP) measurement and 
fundoscopy were conducted. Central macular thickness as measured with Stratus 
TD-OCT (Software Version 5.0; Carl Zeiss Meditec, Dublin CA). The presence, 
location and type of CNV were determined by FFA using the Spectralis (Heidelberg 
Industries, Germany) or Visucam non-mydriatic fluorescein camera (Zeiss 
Engineering, Germany). Patient medical history, concomitant medication and 
previous treatment for nAMD were recorded. Polypoidal choroidal vasculopathy was 
not screened as ICGA was not performed routinely in all cases. Indocyanine green 
angiography was only performed when the clinical presentation and demographics of 
the patient suggested PCV. Patients proven to have PCV were not included in these 
studies.  
2.3.2 - Measurement of visual acuity at baseline and all subsequent visits  
Visual acuity was measured using a standardised protocol by trained clinic staff, 
using Snellen VA charts projected onto a standardised background at 3 meters, with 
results expressed in notation to represent the common testing distance of 6 meters. 
When one eye was tested another eye was occluded. Visual acuity was measured 
using distance spectacles if available, and if a patient did not obtain 6/6 acuity, a 
pinhole occluder with a 1.25mm aperture was used to minimise the effect of 
refractive error. Baseline visual acuity was noted in Snellen VA notation, and the best 
vision recorded was written in the notes (either without correction, with spectacle 
correction, or pinhole correction). If the acuity was worse than 6/60, a stepwise 
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measurement of 3/60, 2/60 and 1/60 was used with a mobile Snellen VA card.  If 
necessary, counting fingers, then hand motions and perception of light was assessed 
at 30cm.  
Visual acuity was measured at every visit.  For the purposes of analysis, and to aid 
comparison of results with established clinical trials which used early treatment of 
diabetic retinopathy study (ETDRS) VA charts, Snellen visual acuity was converted 
to a decimalised value, then to “approximate ETDRS letters” using the following 
formula described by Gregori and Rosenfeld. (165)  
Approximate ETDRS Letters = 85-50 x Log (Decimalised Snellen VA) 
A conversion table for Snellen VA to approximate ETDRS letters is included as Table 
3.  
 
 116 
Table 3 - Conversion table of Snellen visual acuity to Approximate ETDRS Letters 
Snellen VA Approximate ETDRS Letters 
6/6 85.00 
6/7.5 80.15 
6/9 76.20 
6/12 69.95 
6/15 61.14 
6/18 54.90 
6/21 50.05 
6/24 54.90 
6/30 50.05 
6/36 46.09 
6/48 39.84 
6/60 35.00 
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2.3.3 – Optical coherence tomography image acquisition for baseline and 
subsequent follow-up visits 
From June 2007 until March 2009, OCT was performed using a Stratus TD-OCT with 
trained clinic staff using the Fast Macular Thickness Map protocol, capturing 768 A-
scans in a 6mm “star” arrangement (128 A-scans radially arranged 60 degrees 
apart.(166) Due to advancements in OCT imaging technology, SRC upgraded their 
device to a Cirrus SD- OCT system (Software version 4.0, Carl Zeiss Meditec, Dublin 
CA) (Figure 22). The “macular cube protocol” capturing 65536 A-scans in a 6mm 
cube (512x128 A-scans in a continuous cube arrangement was used for all scans. 
Additionally, each patient scanned on the Cirrus system also underwent a “5-line 
high-definition Raster protocol”, which captured 5 high resolution scans aimed in the 
foveal region. Patients in the LTRS cohort transitioned to the Cirrus SD-OCT system 
between March and May in 2009, corresponding to a time point within the 9 – 24 
month window of follow-up from baseline. OCT images since 2011 were performed 
on either the Cirrus or Spectralis OCT scanner. (Figures 22-23) 
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Figure 22 - Cirrus spectral-domain optical coherence tomography scanner at Sydney 
Retinal Clinic 
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Figure 23 - Spectralis Heidelberg retinal angiograph (HRA) (Heidelberg Engineering) 
used for FFA studies at Sydney Retina Clinic 
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Figure 24 - Fluorescein dye used for angiography  
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2.3.4 - Clinical assessments at follow-up visits 
After a 3-month loading period consisting of monthly visits and injections, patient 
follow-up intervals varied between 1 to 6 months depending on disease activity. At 
each visit, Snellen VA measurement, OCT and ophthalmic examination of both eyes 
were performed. FFA and IOP measurement were performed at the discretion of the 
treating physician. The most common indication for repeat FFA was persisting fluid 
seen on OCT refractory to monthly treatment. Repeat IOP measurement was 
performed as a yearly screen, or when the clinical assessment showed evidence of 
IOP increase after the treatment.  ICG was performed if there was a clinical suspicion 
of idiopathic PCV. 
Systemic and ocular AE and SAE were documented from direct patient interview and 
recorded in the clinic notes by clinic staff at each clinic visit. Ocular AE were 
confirmed by eye examinations at the clinic visit. Systemic AEs were reported by 
patients and confirmed by the patient’s general practitioner or other treating 
physician. 
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2.3.5 - Ranibizumab injection protocol and follow-up visits 
Injections were performed under strict asepsis and standardised protocol by a single 
clinician (AC). (167) Patients were prepared via administration of topical anaesthesia 
(Benoxinate hydrochloride 0.4%), followed by application of a topical antimicrobial 
solution (Povidine iodine 5% [Sanofi, Paris, France] or chlorhexidine 0.1% [Pfizer, 
New York, NY] in the case of documented prior iodine allergy) to the conjunctival 
sac. The injection of 0.5mg of ranibizumab (in 0.05ml) was administered using a 30-
gauge needle through the pars plana. Patients were prescribed topical 
chloramphenicol solution 0.5% 4 times daily for 1 week after injection. A follow-up 
phone call to monitor AEs was conducted for all patients within 24 hours of injection.  
All patients received three initial monthly loading doses of 0.5mg ranibizumab and 
subsequent treatment was at the physician’s discretion, with a minimum of 28 days 
between injections.  
Criteria for re-treatment included one or more of the following:  reduction in Snellen 
VA of ≥1 line; persisting exudation or blood at the macula on clinical examination; 
presence of SRF or IRF on OCT; or development of new areas of CNV on FFA. 
Patient follow-up was initially monthly, then less frequently if clinically deemed safe to 
do so based on these criteria.  
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2.4 - Source data collection 
Data collection sheets for baseline patient characteristics were developed and 
refined after several trial runs of data collection.  The finalised data collection sheets 
for the LTRS and SERS are attached as Appendices A - E.  Once a patient had been 
identified for inclusion into either study, their physical medical record was reviewed, 
and data was entered onto the relevant data sheet.  
2.4.1 - Baseline visit for long term ranibizumab study  and second eye 
ranibizumab study 
The first ranibizumab injection date for first and second treatment eyes was identified 
via the practice management electronic database.  The review of the physical patient 
file identified the clinic visit associated with the decision to initiate ranibizumab 
therapy, and this was deemed the “baseline visit.” The clinic record was reviewed for 
the presenting visual symptoms, VA, previous treatment for AMD and other macular 
conditions, notated on the baseline data collection sheet (Appendix A).  Potential 
baseline predictors of response to ranibizumab were identified, including previous 
ocular treatments for nAMD (focal laser, PDT, bevacizumab) concurrent medical 
conditions that may have confounded the results of systemic adverse events 
(ischemic heart disease, stroke, hypertension, hypercholesterolemia, diabetes).  
Quantitative (CMT) and qualitative OCT data was collected by a review of the 
relevant baseline OCT archived images. This is detailed in chapter 2.5. 
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2.4.2 - Follow-up data points (including optical coherence tomography 
For the LTRS, additional data points were 1,2,3,6,12,18,24,30,36,42,48,54 and 60 
months following baseline treatment with ranibizumab. Best corrected VA was 
collected from the patient files, along with the model of OCT machine 
used.(Appendix B). Optical coherence tomography qualitative and CMT data was 
collected from the relevant archived scans at the 60 months following baseline 
injection.  
For the SERS, VA was collected for follow-up data points of 1,2,3,6 and 12-months 
after the baseline treatment date for the second eye.  OCT data was collected from 
the archived scans corresponding to the 12-month visit (Appendix F). Specifics of 
OCT data collection are outlined in Chapter 2.4. 
The patient visit closest to each of these time points was chosen for data collection 
and analysis.  If the visit occurred >1month before or after the data point, the visit 
was classified as “missing data”.   
2.4.3 - Adverse events 
Every visit related to an injection over 60 months for the LTRS, and 12-months for 
the SERS (including the data collection points defined in Chapter 2.4.2) was 
reviewed to record AE and SAE.  The clinic protocol mandated the questioning and 
recording of all adverse events at every patient interaction. 
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2.5 – Optical coherence tomography data grading and analysis  
Archived baseline OCT scans (all performed with Stratus TD-OCT for the LTRS 
cohort, and some performed with the Cirrus SD-OCT for the SERS cohort) and 5-
year scans (97.8% from Cirrus SD-OCT and 2.2% from Spectralis SD-OCT) were 
evaluated by two trained image graders independently, and a third grader 
adjudicated disagreement. For baseline TD-OCT scans, the fast macular thickness 
map protocol was used, comprising of six 6mm radial lines 60 degrees part, with 128 
A-scans in each line. The fovea was assessed for accurate centration within the 
Early Treatment Diabetic Retinopathy Study (ETDRS) grid, and the CMT was 
recorded from the central 1mm zone within this grid. For each of the six radial lines in 
each scan, inner and outer retinal segmentations defined by the Stratus automated 
algorithm were reviewed and redefined if necessary. If these segmentation lines did 
not correspond to the first inner hyper-reflective layer [representing the internal 
limiting membrane (ILM)] and the inner red hyper-reflective band of the larger outer 
hyper-reflective layer (representing the photoreceptor inner segment/outer segment, 
or IS/OS junction), they were manually redrawn with a computer mouse (168, 169) 
and validated by 2 independent observers. Central macular thickness (central 1mm 
zone) was then recalculated after these segmentation lines were redrawn using the 
Stratus version 5.0 review software. (Figures 25 and Figure 26) 
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Figure 25 - Stratus TD-OCT baseline scan with poor automated inner and outer retinal 
boundary demarcation lines  
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Figure 26 - Stratus TD-OCT baseline scan with inner and outer retinal boundary 
demarcation lines manually corrected from Figure 25. Note that the central 1.0mm 
macular thickness has changed from 189um (pre correction Figure 25) to 196um 
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If the inner and outer retinal boundaries were unclear (e.g. significant sub-retinal 
fibrosis, or massive macular oedema exceeding the maximally measured retinal 
thickness) the scan was excluded from analysis. If the fovea was not centred, one of 
the 6 scans transecting the fovea was selected, and a manual calliper calculation of 
CMT utilising 3 points representing the central fovea and 500μm either side was 
recorded (Figures 27-29).  If the fovea could not be identified, the scan was excluded 
from analysis.  
The presence and the type of fluid in OCT at baseline were also recorded by 
individually reviewing each of the 6 scan lines from the fast macular thickness map 
protocol.  
 
 129 
 
Figure 27 - The above image shows the foveal pit, which is decentred from the 
expected position of A-Scan 64.  A-Scan 52 has been selected as the centre of the 
foveal pit, and therefore the centre of the 1mm central macular thickness.  In this case, 
the retinal thickness is 125μm
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Figure 28 - The second retinal thickness point has been selected at A-scan 42, 
representing the nasal border of the 1mm central macular thickness in the left eye 
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Figure 30 - The third retinal thickness point has been selected at A-scan 22, 
representing the temporal border of the 1mm central macular thickness in the left eye. 
All three retinal thicknesses in Figures 27, 28 and 29 were averaged to yield a more 
accurate 1mm central macular thickness compared to if the automated algorithm was 
used 
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For 5-year OCT scans, (Cirrus and Spectralis) foveal ETDRS grid alignment was 
adjusted if necessary, so that the 6mm grid was centred over the fovea. The CMT 
(computer determine average retinal thickness based on all A-scans occupying the 
central 1mm zone) was recorded from the aligned grid. Five-line high-definition (HD) 
raster scans were reviewed to qualitatively describe macular fluid type. (170)  
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2.6 - Fundus fluorescein angiography grading 
Fluorescein angiography baseline images were reviewed and the CNV lesion 
classified as either occult or classic, then the total lesion size was measured using 
the software inbuilt callipers. As follow-up FFA was performed when required, only 
baseline type and location of CNV were analysed. For inclusion in these studies, 
CNV lesions had to show activity in the sub-foveal region (500um from the centre of 
the foveal avascular zone), evidenced by hyperfluorescence involving this region. 
(Figure 30) Two trained graders independently graded images and a third grader 
adjudicated disagreement.  
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Figure 30 - Fundus fluorescein angiography showing hyperfluorescence involving the 
foveal avascular zone.  
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2.7 - Source data entry and verification 
All collected data was entered into Epidata Entry (Epidata Software, Denmark) by 2 
independent data entry personnel, using a double-entry technique (each set of data 
entered once by 2 different data entry personnel.)  Thirty-nine thousand and five 
hundred data points were entered from 250 patient records. Double-entry data 
verification (comparing each of the 2 data sets to the other) was conducted, with the 
Epidata software detecting discrepancies in 1417/39500 data points from 214/250 
records. All of the 1417 discrepancies were checked against the data collection 
sheets, and patient files if necessary, and corrected. During the data collection 
phase, a random audit of 5% of the source data was performed and checked against 
the original data files.  
 
2.8 - Statistical methods  
Snellen VA was converted to ETDRS letters for statistical analyses as described 
above. Paired t tests were used to assess changes in VA and CMT over 5-years in 
the LTRS, and over 1 year in the SERS. Changes in VA compared to baseline were 
classified into three categories of stable (loss or gain of ≤15 letters), improved (gain 
of >15 letters) and worse (loss of ≥15 letters), corresponding to reports from the 
landmark trials. (17, 77)  Two sampled t-tests were used in the SERS to assess 
differences in mean VA between the first and second treated eyes.  
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Baseline VA was stratified into five groups according to criteria of the Australian 
Modification of the 10th revision of the International Classification of Diseases: 
1. legal blindness: baseline VA< 35 letters (Snellen VA< 6/60),  
2. low vision: VA≥ 35 (≥6/60) and < 60 letters (<6/18),  
3. reduced vision: VA ≥60 (≥6/18) and < 70 letters (<6/12),  
4. mildly reduced vision to Australian legal driving limit: VA ≥70 and < 85 letters 
(≥6/12 and <6/6) and  
5. normal vision: VA ≥85 letters (≥6/6).   
Changes in VA and CMT were evaluated separately in each stratified baseline VA 
group, to address the potential confounding effects of “ceiling and floor effect” 
resulting from good or poor baseline vision. One-way analysis of variance (ANOVA) 
was used to compare means of VA and CMT changes, respectively over the 5-years 
across the 5 baseline vision groups. 
Linear regression was used to assess the effects of age, gender, number of 
injections, previous treatment, medical history, medications and baseline VA on both 
VA and CMT changes.  The relationships between treatment outcomes and fluid type 
or CNV type were also analysed. 
Visual acuity and CMT changes over a 5-year period on previous treatment naïve 
patients were evaluated, and an ANOVA was performed to compare changes in VA 
and CMT respectively between treatment naïve patients and non-treatment naïve 
patients. 
All analyses were carried out using the Statistical Package for Social Sciences 
(SPSS, version 19), and a p-value of 0.05 was used to signify statistical significance 
in these studies.  
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CHAPTER THREE - Long-term outcomes of 
intravitreal ranibizumab for neovascular age-related 
macular degeneration in clinical practice  
 
3.1 - Background 
There is limited data available on long-term outcomes of eyes treated with an 
individualised treatment regime. (153, 154, 158) As patients often continue to 
undergo treatment with anti-VEGF agents for many years, the long-term safety and 
efficacy of therapy under such treatment protocols are clinically relevant, and are 
currently unknown. (171) 
The LTRS aimed to evaluate visual and anatomical outcomes of an individualised 
regime of ranibizumab therapy on patients with nAMD over 5-years. The baseline 
prognostic factors of long-term treatment response and the safety profile of treatment 
were also assessed.  
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3.2 - Methods 
3.2.1 - Study design 
This is a retrospective study of consecutive patients treated with intravitreal 
ranibizumab for subfoveal nAMD. The study was conducted in a single tertiary 
referral retinal clinic and all patients were assessed and treated by a single physician 
(AC) according to standardised retreatment criteria.  
3.2.2 - Patient eligibility 
Inclusion and exclusion criteria for the LTRS are outlined in Chapter 2.2.  
3.2.3 - Patient assessment at baseline visit and follow-up visits 
At each visit, Snellen VA, OCT, ophthalmic examination and fundoscopy were 
performed. OCT findings were used as a guide for treatment as described in Chapter 
3.2.5.  At the 5-year visit, OCT scans were performed using either a Cirrus or 
Spectralis OCT. Please refer to Chapter 2.3 for further details.  
3.2.5 - Treatment regime 
Injections were performed in an operating theatre under a standard protocol.(167) All 
patients received three initial monthly loading doses of 0.5mg ranibizumab and 
subsequent treatment was at the physician’s discretion.  
Criteria for re-treatment included one or more of the following:  reduction in Snellen 
vision of ≥1 line; persisting exudation or blood at the macula on clinical examination; 
presence of SRF or IRF on OCT; or development of new areas of CNV on FFA.  
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3.2.6 - Optical coherence tomography analysis 
Baseline scans (all using Stratus TD- OCT) and 5-year scans (97.8% from Cirrus 
SD-OCT and 2.2% from Spectralis SD-OCT) were evaluated by two trained image 
graders independently, and a third grader adjudicated disagreement. CMT and 
qualitative OCT findings (IRF, SRF) were assessed and recorded. Further details on 
the technical aspects of the scan analysis are described in Chapter 2.5  
3.2.7 - Fundus fluorescein angiography grading 
Grading was performed as described in Chapter 2.6.   
3.2.8 - Statistical methods  
Snellen VA was converted to ETDRS letters for statistical analyses (165). Paired t-
tests were used to assess changes in VA and CMT over 5-years.   
One-way analysis of variance was used to compare means of VA and CMT changes, 
respectively over the 5-years across the 5 baseline vision groups. 
Linear regression was used to assess the effects of age, gender, number of 
injections, previous treatment, medical history, medications and baseline VA on both 
VA and CMT changes.  The relationships between treatment outcomes and fluid type 
or CNV type were also analysed.  Further details are outlined in Chapter 2.8. .       
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3.3 - Results 
3.3.1 - Overview: 
Of 886 patients with nAMD who commenced ranibizumab treatment between June 
2007 and May 2008, 369 completed 5-years follow-up, and 208 eyes from 208 
patients were included in the study. (Figure 31) Patient general baseline 
characteristics are presented in Table 4, and ocular baseline characteristics in Table 
5.  
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Figure 31 - Schematic diagram of patient selection showing inclusion and exclusion 
from the study analyses.  
886 
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5 years of follow up
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up
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89
Underwent treatment with 
Ranibizumab prior to government 
funding resulting in variable access
19
Treatment by another physician
16
Photodynamic therapy during study
16
Bevacizumab during study
2
Triamcinolone during study
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Table 4 – General baseline characteristics of patients with neovascular age-related 
macular degeneration that completed 5-year follow-up 
 
Characteristic Mean (SD) or Frequency (%) 
    
General   
  Age (years) 78.4 (7.2)* 
  Sex (male) 65/208 (31.3) 
  Study Eye (right) 114/208 (54.8) 
  Baseline Visual Acuity (letters) 53.6 (19.3)* 
    
Medical History   
  Cardiovascular Disease 31/208 (14.9) 
  Stroke 19/208 (9.1) 
  Hypertension 143/208 (68.8) 
  Hypercholestraemia 95/208 (45.7) 
  Diabetes mellitus 25/208 (12.0) 
  
SD = standard deviation 
*Mean (SD) 
†8/208 (3.8%) had cataract surgery in the study eye during the 5 year treatment 
period 
‡Missing participant data  
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Table 5 - Ocular baseline characteristics of patients with neovascular age-related 
macular degeneration that completed 5-year follow-up 
 
Characteristic Mean (SD) or Frequency (%) 
    
Choroidal Neovascularisation Subtype   
  Occult 124/170 (72.9) 
  Minimally Classic 32/170 (18.8) 
  Predominantly Classic 9/170 (5.3) 
  Classic 5/170 (2.9) 
    
Optical Coherence Tomography   
  Baseline Central Macular Thickness (CMT) 256.7 (88.0)* 
  Intra-retinal Fluid (IRF) 97/208 (46.6) 
  Sub-retinal Fluid (SRF) 9/208 (4.3) 
  Mixed IRF/SRF 65/208 (31.3) 
  No Fluid 12/208 (5.8) 
  Data not available 25/208 (12.0) 
    
Lens Status (study eye only)   
  Phakic 145/208 (69.7)† 
  Pseudophakic 63/208 (30.3) 
    
Treatment (study eye only)   
  Treatment Naive 71/208 (34.1) 
  One or more previous nAMD treatment 137/208 (65.9) 
    
Previous Treatment Methods (study eye only)   
  Photodynamic Therapy 79/208 (38.0) 
  Focal Laser 29/208 (14.0)‡  
  Bevacizumab 114/208 (54.8) 
  Bevacizumab and Photodynamic Therapy 54/208 (26.0) 
    
SD = standard deviation   
*Mean (SD)   
†8/208 (3.8%) had cataract surgery in the study eye during the 5 year treatment 
period 
‡Missing participant data   
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3.3.2 - Visual acuity   
Mean baseline VA of the 208 eyes was 53.6 (±19.3). As shown in Figure 32, 
maximum visual gain occurred at 6 months with an average of 3.2 (±10.4) letter 
increase when compared to baseline (p<0.0005). Statistically significant visual gain 
of 1.9 letters (p=0.017) was maintained over 1 year. There were no significant 
changes from baseline VA to the end of 2, 3 and 4 years (p> 0.05 for all time points). 
Vision had declined slightly by 2.4 letters at 5-years (p=0.043). At the end of year 5, 
23 (11.1%) patients had improved VA, 143 (68.8%) patients had stable VA, and 42 
(20.2%) patients experienced VA loss (Figure 33). 
Table 6 summarizes average VA changes over 5-years of the treatment in stratified 
baseline VA groups. Patients with poor baseline VA (<35 letters) had a greater VA 
improvement (+11.5 letters, p=0.01) while patients with good VA at baseline (≥ 70 
and < 85) had VA that declined over 5-years (-12.9 letters, p=<0.0005). 
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Figure 32 - Change in visual acuity associated with ranibizumab treatment over a 5-year period. 
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Figure 33 – Proportion of patients with visual acuity improvement  (>15 letters) VA stability (Gained <15 letters and Lost <15 letters) and VA loss 
(Lost >15 letters) of years 1-5 compared to baseline 
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Table 6 - Change in visual acuity over 5-years following the commencement of ranibizumab treatment, in relation to baseline visual acuity 
 
Group 
Baseline Visual 
Acuity  (ETDRS letters) 
n 
5-Year Change in Visual Acuity 
Mean (95% CI) 
(ETDRS letters) 
p-value 
1 < 35 22 11.5 (5.2, 17.9) 0.001 
2 ≥ 35 and < 60  100  -0.6 (-3.2, 2.0) 0.655 
3 ≥ 60 and < 70 46  -3.7 (-8.2, 0.9) 0.113 
4 ≥ 70 and < 85 34  -12.9 (-19.2, -6.6) <0.0005 
5 ≥ 85 6  -15.8 (-51.5, 19.9) 0.307 
          
ETDRS = Early Treatment Diabetic Retinopathy Study 
 
  
n = sample size 
   
  
CI = confidence interval       
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Baseline VA remained a significant predictor for VA change over 5-years, after 
adjusting for possible confounders of total number of injections and age (Table 7). 
Other baseline characteristics including age, existing medical history, concomitant 
medication and previous treatment history were not associated with the change in VA 
(data not shown).
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Table 7 - Linear regression analysis of visual acuity change over 5-years.  
 
Group 
Baseline Visual Acuity 
(ETDRS letters) 
n 
Regression 
Coefficient† (95% CI) p-value 
4 ≥ 70 40 Reference  - 
3 ≥ 60 and < 70 45 11.2 (4.9, 17.4) <0.0005 
2 ≥ 35 and < 60 100 16.1 (10.5, 21.6) <0.0005 
1 < 35 23 30.7 (22.8, 38.6) <0.0005 
Baseline age*  -  -  -0.1 (-0.4, 0.1) 0.345 
Total ranibizumab injections*  -  - 0.3 (0.1, 0.4) <0.0005 
          
ETDRS = Early Treatment Diabetic Retinopathy Study; n= sample size; CI = confidence interval 
* Added into regression model. 
†Change in visual acuity (number of ETDRS letters read) compared to the reference group, over a 5-year period. 
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3.3.3 - Previous treatment naïve patients 
Fifty-eight patients (27.9%) were treatment naïve patients at the baseline. The 
statistical analysis indicated that there were no significant difference at 5% 
significance level in any VA changes or CMT change over 5-years period between 
patients in treatment naïve and those in non-naïve treatment group (p > 0.05).   
3.3.4 - Central macular thickness  
Central macular thickness data was available for 180 patients who had gradable 
baseline on Stratus TD-OCT and 5 year OCT measurements on Cirrus SD-OCT. A 
total of 28 patients had scans where the CMT could not be measured due to poor 
image quality. For all patients, the changeover from Stratus to Cirrus occurred 
between March and May 2009, which fell between the 9 and 24-month follow-up 
period.  The transition was consistent for all patients. CMT decreased by an average 
of 28.3µm (P<0.0005) from baseline (256.7 ±88.0µm) to 5-years (228.4 ±77.8µm). A 
greater baseline CMT was associated with a greater reduction in CMT after 5-years 
(p<0.0005).  Age, total number of injections and previous treatment was not 
associated with the changes in CMT, after adjusting for baseline CMT. No correlation 
was identified between baseline CMT and VA changes over 5-years (r = 0.082, 
p=0.272).  
3.3.5 - Impact of baseline retinal fluid type on visual acuity and central macular 
thickness changes 
Patients were divided into five categories with regards to their baseline fluid status. 
These categories were IRF (97/208 patients, 46.6%), SRF (9/208, 4.3%), mixed 
IRF/SRF (65/208, 31.3%), no retinal fluid (12/208, 5.8%) and patients whose data 
could not be assessed (12/208, 5.8%). The unavailable data resulted from data 
transfers following device software upgrading and changes in information technology. 
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There was no significant difference in VA and CMT value changes across the 5 fluid 
type groups over 5 year period after adjusting the baseline VA and CMT (P=0.901 
and 0.573 respectively).  
3.3.6 - Baseline choroidal neovascularisation type and treatment outcomes 
Baseline FFA images were available on 170 of 208 (81.7%) patients at the time of 
image grading. Images that were lost resulted from data transfers following device 
software upgrading and changes in information technology.  The majority of CNV 
type were occult followed by minimally classic and predominant classic (18.8% and 
5.3%) respectively.  There was no statistical significant difference in VA change 
across CNV types over the 5-year study period (p = 0.910). In analysing the 
relationship of CMT and baseline CNV types, no significant difference in CMT 
change over 5-years was found across CNV types (p = 0.160). 
3.3.7 - Number of injections 
The average number of injections per year was 7.5 (±2.6), 5.8 (±3.9), 6.4 (±4.5), 5.6 
(±4.5) and 5.8 (±4.7) for years 1, 2, 3, 4 and 5, respectively. The average number of 
injections over 5-years was 30.8 (±17.4). Total number of injections was positively 
related with the change in VA over 5-years (p<0.0005) after adjusting for age and 
baseline VA (Table 7).  The number of injections required by patients in each year of 
follow-up is expressed as a proportion of the total cohort (Figure 34) 36% of patients 
did not require an injection in their 5th year of follow-up, whilst 24% of patients 
required near monthly (10-12) injections in the 5th year.
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Figure 33  - The proportions of all patients (n=208) in each year that required no 
injection, 1-3, 4-6, 7-9 or 10-12 injections.  
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3.3.8 - Adverse events 
The most frequent ocular AEs were floaters (17.8%), eye pain (17.8%) and epiphora 
(6.3%). Ten patients (4.8%) had elevated IOP (>30mmg Hg), which was controlled 
with topical anti-glaucoma medication. There were no cases of endophthalmitis, 
retinal tear, retinal detachment or lens trauma observed (Table 8). 
Falls occurred in 22.6% of patients during the 5-years. Myocardial infarction, 
transient ischaemic attack, cerebral vascular accident (CVA) and coronary artery 
disease (CAD) were reported in 3.8%, 2.4%, 1.9% and 1.0% of patients, 
respectively. Other SAEs including angina, cancer and infections were low (all 
<0.5%) (Table 9). 
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Table 8 - Ocular adverse and serious adverse events in patients receiving ranibizumab 
therapy over a 5-year period (n=208) 
 
Category 
Number of Patients* 
(%)  
    
Ocular Adverse Events 126 (60.57) 
Pain 37 (17.79) 
Floaters 37 (17.79) 
Epiphora 13 (6.25) 
Elevated Intraocular Pressure 10 (4.81) 
Subconjunctival Haemorrhage  10 (4.81) 
Flashes 9 (4.33) 
Discharge from Eye 3 (1.44) 
Lid Swelling 2 (0.96) 
Conjunctivitis 2 (0.96) 
Chalazion (study eye) 1 (0.48) 
Ectropion (study eye)  1 (0.48) 
YAG (both eyes)  1 (0.48) 
    
Ocular Severe Adverse Events 19 (8.64) 
Cataract Surgery 8 (3.84) 
Vitreous Haemorrhage 2 (0.96) 
SRH (causing VA reduction) 2 (0.96) 
VMTS (study eye) 1 (0.48) 
Corneal Abrasion 1 (0.48) 
Corneal Abscess 1 (0.48) 
Macular Hole 1 (0.48) 
Recurrent Eye Infections 1 (0.48) 
Ptosis (study eye) 1 (0.48) 
    
*Several patients had multiple adverse events 
YAG = Yttrium Aluminium Garnet Laser 
SRH = Sub-retinal Haemorrhage   
VMTS = Vitreo-Macular Traction Syndrome 
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Table 9 - Non-ocular adverse and serious adverse events in patients receiving 
ranibizumab therapy over a 5-year period (n=208) 
 
Category 
Number of Patients 
(%)  
    
Non-Ocular Adverse Events 48 (23.08) 
Falls 47 (22.6) 
Headaches and Nausea 1 (0.48) 
    
Non-Ocular Severe Adverse 
Events 
24 (11.54) 
Myocardial Infarct 8 (3.84) 
Transient Ischaemic Attack 5 (2.40) 
Stroke 4 (1.92) 
Coronary Artery Disease 2 (0.96) 
Cardiac/Heart Failure 1 (0.48) 
Angina 1 (0.48) 
Valve Replacement 1 (0.48) 
Atrial Fibrillation 1 (0.48) 
CABG 1 (0.48) 
    
CABG = Coronary Artery Bypass Grafting 
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3.4 - DISCUSSION  
3.4.1 - Differences in patient characteristics between real-world cohorts and 
clinical trials 
A baseline VA of greater than 6/12 (Snellen) was found in 40 (19%) patients in the 
LTRS cohort. Clinical trials often exclude patients with vision > 6/12. This limits 
possible VA gains due to a “ceiling” effect. In addition, this study included eyes that 
had received previous treatment for nAMD, and eyes with broader lesion types such 
as pigment epithelial detachment and extensive haemorrhages, which were excluded 
from some trials. (17, 77)  The inclusion of these patients makes direct comparison 
with other clinical trial results difficult, however they represent the spectrum of 
disease treated in a real clinic setting.  
3.4.2 - Long-term mean visual acuity 
The majority of patients (79.8%) in this study cohort improved or maintained their 
vision over 5-years (losing .≤15 letters compared to baseline). The maximal average 
VA gain of 3.2 letters was observed after the first 6-months and slightly declined to 
approximately 2.0 letters at the end of one year. The results are consistent with 
previous long-term findings from clinic-based anti-VEGF therapy. (153, 154) The 
proportions of stable vision (losing <15 letters) and visual gain (gain >15 letters) at 1 
year was less than the 1 year results in clinical trials. (17, 118) The differences in the 
degree of improvement are likely due to the differences in the baseline 
characteristics between trial patients and those in a real world setting as outlined in 
Chapter 3.4.1.
 157 
3.4.3 - The relationship between baseline visual acuity and 5-year visual acuity 
Patients who had poor baseline VA showed a statistically significant improvement in 
VA while patients with good baseline VA trended towards a decline in their vision 
over 5-years (Table 7). This is consistent with the report of Pushpoth et al, (154) but 
contrasts with Rasmussen’s study, which found that patients with a baseline VA 
<6/30 Snellen had stable vision over 4 years. (158) Patients with VA< 6/60 may have 
very little potential for further measurable visual loss, exhibiting a “floor” effect of low 
VA change. Approximately 20% of patients with baseline Snellen VA better than 6/12 
did not have the potential to improve their measured VA by >15 letters (“ceiling 
effect). Of these, six patients with baseline VA in normal range had the greatest VA 
decline over the five years although the decrease was not statistically significant, 
likely due to the small sample size. The difference between overall mean VA and the 
VA outcomes adjusted by baseline VA may suggest that mean VA results from whole 
cohort on both previous treatment naïve and non-treatment naïve patients 
sometimes may mask good and poor responders to treatment.  
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3.4.4 - The relationship between the number of injections and 5-year visual 
acuity 
A positive relationship was observed between number of injections and 5-year visual 
change. This equates to an increase of 0.3 letters in the 5-year VA for every increase 
of 1 injection (Table 7). This association is consistent with findings that more frequent 
injections produce better visual outcomes. (172, 173) However, in this cohort, the 
mean total number of injections over five years was 30.8, which is approximately half 
of the number injections that would be administered under a monthly regime. This 
finding demonstrates that vision may be maintained with less than monthly injections 
if regular review and assessment of disease activity is conducted.  
3.4.5 - Anatomical outcomes 
Previous studies investigating the response of fluid subtypes to ranibizumab therapy 
have shown that changes in SRF correspond with BCVA changes (174, 175). Recent 
studies have shown that at baseline, SRF is a favourable prognostic marker of visual 
outcomes, whereas IRF is a poor prognostic marker of the same. (140) In the LTRS 
cohort, neither fluid subtype was more responsive to ranibizumab therapy following 
long-term treatment.  It is possible that there was no difference between fluid types 
was found in this cohort, as only a small proportion of patients had SRF at baseline 
(9 patients) meaning that a true difference would have been difficult to detect. 
Some previous studies have demonstrated a relationship between vision and CMT 
(129) (175). Others found no correlation, especially when the SRF and IRF 
components were not separated in the measurement. (174) There was no correlation 
between CMT and 5-year VA in this study, possibly due to fact that when CMT was 
measured, any present SRF was included in the value.  
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3.4.5.1 - Challenges with accounting for several optical coherence tomography 
machines 
There is little published data regarding the CMT changes in retrospective long-term 
studies, most likely due to difficulties in measurement and data collection. Central 
macular thickness was measured with different OCT devices during follow-up due to 
technology advances from TD-OCT to SD-OCT, which reflects changes that 
occurred in retinal clinics during this period. (176) Previous studies have showed that 
TD-OCT and SD-OCT are not interchangeable as Stratus OCT measures the 
thickness of the retina as the distance between the inner limiting membrane (ILM) 
and the IS/OS junction of the photoreceptors, Cirrus SD-OCT measures from the 
anterior border of the retinal pigment epithelium (RPE) to the ILM, while Spectralis 
OCT measures the distance from the posterior border of the RPE to the ILM. (177) 
Therefore, Spectralis OCT gives higher readings of macular thickness than Cirrus 
and Stratus OCT.(166, 169) This study covered a 5-year period. During the baseline 
period, only Stratus OCT was available.  This was upgraded to SD-OCT shortly after 
the technology became available.  Assessments were switched over to the higher 
resolution scanners with increased potential to detect fluid. As with most other study 
protocols, OCT examinations used for retreatment decisions utilised the currently 
available OCT device. In early randomised AMD clinical studies such as the 
Comparison of AMD Treatment Trials (CATT) and Prospective OCT Study with 
Lucentis for Neovascular AMD (PrONTO) TD-OCT was used. (129, 132) The CATT 
study used Stratus TD-OCT in the first year then changed over to Cirrus SD-OCT for 
22.6% of scans in the second year.(118) (176) The retreatment decision in these 
trials was based on the presence of fluid in sub-retina detected by Stratus OCT 
including fast macular thickness map protocol.(118, 176) To compare the 
measurements from TD-OCT and SD-OCT a number of algorithms may be used. 
Bland and Altman devised a method of evaluating agreement between 
measurements of two devices by plotting their difference against their mean. The 
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measurements can be used interchangeably when the 95% CI of agreement is 
within a clinically acceptable range. (178) Hatef calculated retinal thickness from 
different devices by defining an internal and external retinal layer position using the 
intrinsic retinal segmentation algorithms in each device then averaged retinal 
thickness within nine retinal subfields in a 6 mm diameter circle centred on the 
fovea. (170) By manually measuring paired CMT on TD-OCT and SD-OCT obtained 
from the same patient, CATT study reported the absolute measurement difference 
was 25 µm or less in 71% of paired scans between two devices. (176) 
In this study, 4 patients whose CMT was measured with Spectralis OCT at the 5 year 
assessment were excluded to avoid the possible significant differences and 
inconsistency of CMT measurements between Cirrus OCT and Spectralis OCT.  In 
addition, measures were taken to reduce any possible variability by manually 
correcting segmentations and centralisation of fovea as needed. Based on the 
situation that the Stratus device records lower CMT values than Cirrus, the reduction 
in CMT seen with ranibizumab treatment in this study likely demonstrates a true 
finding as the trend of the Stratus machine to obtain lower CMT values would 
generally lead to an underestimation of any difference over 5-years by reducing the 
baseline value. 
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3.4.6 - Adverse events 
Systemic SAE frequency for vascular thrombotic events, such as CVA was similar to 
other reported findings. (136) The total AE rate in this study was lower than for other 
published clinical trials. (118) Falls have not been previously reported in a 
retrospective long-term ranibizumab study. The LTRS found that falls occurred in 
22.6% patients over 5 year period, giving an average yearly fall rate of 4.4%. This is 
similar to the 4.9% 1-year fall rate in the ranibizumab arm of the VEGF Trap-Eye: 
Investigation of Efficacy and Safety in Wet AMD (VIEW) study (136).  
The LTRS found a low risk of serious ocular adverse events, comparable to the 
literature (endophthalmitis, with a quoted rate of 0.028%, or 1/3544 injections in a 
meta-analysis). (179) A high proportion of LTRS patients (24%) received 10-12 
injections per month in the 5th year of treatment. Therefore, this population of patients 
would receive approximately 60 injections over 5-years, and statistically 1/59 of these 
patients would suffer from endophthalmitis (a potentially blinding condition, 3544/60 = 
59.06) over 5-years.  This extrapolated statistic could be considered to be more 
alarming than quoting a rate of 1/3544 injections, and helps frame the risk of 
treatment into context when considering the risk/benefit equation of treatment.  
The relatively low SAE rate in the LTRS may relate to fewer injections during the 
longer follow-up period. The single treating physician in a single study centre with an 
established standard practice protocol for the patient assessment, treatment in an 
operating theatre setting and post treatment phone call follow-up may also have 
contributed to the lower rate of AEs and SAEs. (167, 180, 181)
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3.4.7 - Strengths and limitations of the study 
The strength of this retrospective study lies in the carefully designed protocol with 
strict inclusion and exclusion criteria, data collection time points, standardised re-
treatment criteria and consistent clinical assessment and treatment by a single 
physician. This study differs from other published retrospective long-term 
ranibizumab studies, as it has analysed a considerably large number of participants 
(208) all with a 5-year follow-up with no more than a 6-month break between visits. 
The major limitation of this study is its retrospective design, therefore increasing the 
amount of missing data. Other limitations of the study include difficulties reporting 
cataract progression due to non-standardised lens grading at each visit and the use 
of multiple OCT devices, which may have impacted on data accuracy. Although 
justifications of the CMT values between different OCT machines have been made in 
this study, variability of these measurements may still remain. In addition, the ICGA 
screening for PCV was not performed regularly at the baseline. The patients who 
were not responsive to treatment may potentially have included PCV patients. 
 163 
3.5 - Conclusions 
Ranibizumab is an effective therapy for nAMD patient using a disease activity guided 
individualised treatment model, particularly for patients with poor baseline vision. It 
provides stable vision in the majority of nAMD patients over 5-years of treatment. It is 
a safe long-term therapy, with relatively low AE rates. A greater number of injections 
are associated with improved visual outcomes, suggesting that regular treatment is 
of benefit even beyond the initial phase of treatment.  
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CHAPTER FOUR - Bilateral and sequential 
neovascular age-related macular degeneration: 
clinical presentation and treatment 
4.1 - Background 
Second eye nAMD disease is common, and its onset is often unpredictable and 
silent. (42) Prior to the widespread availability of OCT, clinicians were alerted to the 
possible presence of nAMD by visual symptoms, VA decline, or haemorrhage and 
exudation identified at the posterior pole with biomicroscopy. (63) Patients generally 
presented for ophthalmic assessment only when visual symptoms were noticed. (58)  
During scheduled visits to assess the clinical response and progress of the first 
treated eye, opportunities exist to detect nAMD in the second eye. Most nAMD trials 
have excluded the data of second treated eyes, (182) therefore the clinical 
presentation and treatment outcomes of choroidal neovascularisation in second eyes 
is limited.. Furthermore, there is limited population based data assessing the role of 
AMD second eye screening. (183) The Amsler grid has been used as a screening 
tool for decades, but its ability to detect visual disease has remained in doubt in 
several studies (51) and it may not be a sufficiently sensitive instrument for 
monitoring vision. (52, 53)  
 
The purpose of this study is to assess a cohort of patients with bilateral nAMD in 
whom the second eye was diagnosed with nAMD whilst the first eye was undergoing 
ranibizumab IVT, and therefore regular OCT imaging. VA outcomes, and OCT fluid 
characteristics were compared between first and second treated eyes, and 
presenting clinical features of the second eye were assessed. 
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4.2 - Methods 
4.2.1 - Study design 
The study population comprised a retrospective case series of all patients who 
commenced unilateral treatment with ranibizumab for nAMD at a tertiary referral 
retinal clinic between July 2007 and March 2012. Patients who subsequently 
commenced ranibizumab treatment in their second eye, with at least 12-months of 
follow-up for both eyes by a single ophthalmologist were included in the study.  
Exclusion criteria included prior treatment in either eye with ranibizumab, 
bevacizumab or triamcinolone, vitrectomised eyes, PDT, focal laser or cataract 
surgery during the duration of the follow-up period.  
 
4.2.2 - Second eye assessment 
Patients being treated for nAMD in their first eye attended the clinic for assessment 
prior to each intravitreal injection. At each visit, measurements of Snellen VA using 
habitual correction and pinhole, and OCT examination was performed for both eyes, 
with the second eye OCT closely examined for the development of nAMD.  New IRF 
or SRF detected by OCT posed an indication for FFA, which confirmed the presence 
of CNV in the second eye. Further details regarding patient assessment are in 
Chapter 2. 
4.2.3 - Treatment protocol, optical coherence tomography analysis and fundus 
fluorescein angiography grading and statistical methods 
As described in the general methods (Chapter 2) 
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4.3 - Results 
A total of 45 patients satisfied the inclusion criteria. The mean time between 
diagnosis of second eye disease and previous clinic visit was 47.6 ±19.8 days. 
Baseline characteristics and injection characteristics of these patients are presented 
in Table 1. All patients underwent FFA imaging to confirm nAMD, however 7 cases 
could not be adequately graded retrospectively. 
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Table 10 - Baseline and injection characteristics of patients in the second eye 
ranibizumab study (n=45) 
 
Characteristic 
Mean (SD) or 
Frequency (%) 
    
General   
  Age at first eye diagnosis (years) 79.4 (6.5)* 
  Age at second eye diagnosis (years) 80.7 (6.5) * 
  Gender – male 18/45 (40) 
  First treated eye – right eye / left eye 27/45 (60) 
  Baseline Visual Acuity first treated eyes (letters) 56.0 (20.6)* 
  Baseline Visual Acuity second treated eyes (letters) 62.2 (20.7)* 
  Second treated eye being the better seeing eye at 
baseline 
29/45 (64.4) 
    
FFA Characteristics of first treated eyes   
  Occult lesion 34/43 (79.1)‡ 
  Classic lesion 9/43 (20.9)‡ 
  Lesion Size 4.68mm2 (4.6) * 
    
FFA Characteristics of second treated eyes   
  Occult lesion 33/38 (86.87)‡ 
  Classic lesion 5/38 (13.2)‡ 
  Lesion Size 3.97mm2 (4.7) * 
    
Time from last review to second eye diagnosis   
  Mean 47.6 days (19.8) * 
    
Number of injections over first 12-months of 
treatment 
  
  First treated eyes 7.47 (2.63) * 
  Second treated eyes 7.69 (3.0) * 
    
SD = Standard Deviation   
FFA = Fundus Fluorescein Angiography   
*Mean (SD)   
‡Missing participant data (FFA scans not accessible 
for analysis (2 first eyes, 7 second eyes) All of these 
patients had IRF or SRF visible at baseline) 
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4.3.1 - Clinical profile of second treated eyes at diagnosis 
Fifty-three per cent (24/45) of patients with second eye nAMD were asymptomatic on 
presentation (Figure 1). Eighteen patients of the total cohort (40%) were 
asymptomatic and also did not demonstrate a reduction in VA compared to their 
previous visit. Thirty-eight per cent (17/45) of patients had a reduction in VA of ≥5 
letters from their previous visit.  
Amongst the patients who were symptomatic in the second eyes (47%, 21/45), the 
most common symptom was “blurred vision” (62%) followed by metamorphopsia 
(24%). Of these symptomatic patients, 48% (10/21) also had a VA reduction of ≥5 
ETDRS letters compared to the previous visit. 
Intra-retinal fluid and/or sub-retinal fluid detected with OCT were the only clinical 
findings in 62% (15/24) of asymptomatic patients at diagnosis of second eye nAMD, 
and 33% (15/45) of all patients diagnosed with second eye disease. An illustrative 
example of an asymptomatic patient’s imaging and outcomes is shown in Figure 36. 
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Figure 35 - Second treated eye clinical presentation: Optical coherence tomography characteristics at baseline and indications for diagnostic 
fundus fluorescein angiography study
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Figure 36 - Images of the second treated eye of an asymptomatic patient presenting 
nAMD at routine follow-up of first treated eye undergoing ranibizumab injections. 
Second eye VA was 85 letters (Snellen VA 6/6) at baseline. Spectral-Domain OCT of the 
second eye at the previous visit, 28 days prior to baseline. (A) OCT at baseline; an aligned 
image to the previous visit with the arrow indicating new SRF. (B) 2 month OCT image 
aligned to baseline showing positive response following 2x monthly injections of ranibizumab, 
with the SRF no longer visible.  (C) Aligned OCT image at 12-months, showing no SRF and 
flattening of pigment epithelial detachments seen at baseline and 2 months. VA at 12-months 
was 83 letters (Snellen VA 6/6.7). (D) Mid-venous phase fluorescein angiography at baseline 
(E), with a late phase fluorescein angiography showing an increased area of 
hyperfluorescence involving the foveal region consistent with an occult (Type 1) choroidal 
neovascular membrane. (F) 
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4.3.2 – Optical coherence tomography characteristics  
Analysis of qualitative OCT changes (IRF/SRF) was restricted to the 37 patients who 
had a full set of OCT data at baseline and 12-month for both first and second eyes, 
with the remaining 8 patients having ungradable OCT images that were of poor 
quality in at least one of these 4 data collection points. One asymptomatic, second 
eye had a baseline OCT image that was not gradable (Figure 35).  
Presence of Intra-retinal Fluid and Sub-retinal Fluid: 
In second treated eyes, IRF was present in 54% of cases at baseline compared with 
84% in first treated eyes (p=0.01).  At 12-months, IRF was present in 22% of second 
treated eyes compared with 54% of first treated eyes (p<0.01) (Table 11). Sub-retinal 
fluid was present in 49% of cases of second treated eyes at baseline compared with 
41% in first treated eyes (p=0.64).  At 12-months, SRF was present in 14% of second 
treated eyes compared with 6% of first treated eyes (p<0.01) (Table 11). 
Fluid free status after treatment: 
In eyes with IRF or SRF visible on baseline OCT, second treated eyes had a higher 
fluid free state (no visible IRF or SRF) compared with first eyes, following 12-months 
of treatment (70% vs. 41%, p=0.02,Table 11). 
   
Central macular thickness: 
Mean CMT of second eyes was 50 µm lower than first eyes at baseline (p=0.03). 
Mean CMT of first treated eyes decreased by 76µm (from 307µm to 221µm) after 12-
months compared to baseline (p=<0.001). Second treated eyes decreased by 24µm 
(from 257µm to 225µm) after 12-months compared to baseline (p=1.0).  
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Table 11 – Optical coherence tomography characteristics at baseline and 12-months post treatment comparing the same cohort of patients.  
 
 
 
Baseline 12-months post treatment 
OCT 
Characteristic 
(n=37*) 
First eye Second eye p-value First eye Second eye p-value 
IRF  
84% 
(31/37) 
54%                 
(20/37) 
0.01 
54%               
(20/37) 
22%                
(8/37) 
0.01 
SRF  
41%                 
(15/37) 
49%                
(18/37) 
0.64 
6%                   
(5/37) 
14%                   
(5/37) 
1 
Fluid Free  
0%                
(0/37) 
8%              
(3/37) 
0.24 
41%               
(15/37) 
70%              
(26/37) 
0.02 
CMT                
(μm) 
307                       
(SD +/- 77) 
257                      
(SD +/- 61) 
0.03 
221                       
(SD +/- 
76) 
225                  
(SD+/- 44) 
0.76 
*8/45 patients had an incomplete OCT data set, and therefore excluded from this analysis 
 -At baseline, nine first eyes and four second eyes had both IRF and SRF on OCT 
- At 12-months post treatment, three first eyes and two second eyes had both IRF and SRF on 
OCT 
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4.3.3 - Visual acuity at baseline and at 12-months post ranibizumab therapy 
The mean baseline VA in the first eye was 56.1±20.6 letters, compared with 62.2 
±20.2 letters in the second eye of the same patient (Figure 37), representing a 
difference of 6.1 letters (p=0.12). At 12-months following treatment, mean VA in the 
first eye improved by 1.7 letters compared to baseline although not statistically 
significant (p=0.49) and mean second eye VA increased 0.7 letters compared to 
baseline (p=0.69). There was no significant difference in mean VA change between 
the first eye and second eye in the same patient over the 12-month follow-up period 
(1.0 letters difference, p=0.36) 
Second eyes had a higher rate of visual stability compared to first eyes if their 
baseline VA was of >76 letters (Snellen 6/9). Eighty-two per (9/11) cent of second 
eyes maintained VA of >76 letters at 12-months compared with 12% (1/8) of first 
eyes (p=0.05, Table 3). Baseline mean VA in this subgroup was 81.9 ±2.76 letters for 
the second eye vs. 79.0 ±2.44 letters for the first eye (p=0.03). The 12-month mean 
VA of second eyes in this subgroup was 77.4 ±6.2 letters compared to 64.2 ±13.2 
letters in first eyes (p=0.02, Table 12). 
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Figure 37 - Aligned mean visual acuity letter scores of the first treated eye and second treated eye of the same patient over the first 12-months of 
ranibizumab therapy in each eye  (n=45) 
 176 
 
 
Table 12 – Visual acuity stability and optical coherence tomography findings between first and second eyes at 12-months, according to subgroups 
with good baseline visual acuity 
VA 
Subgroup 
Treatment 
eye 
n 
Baseline 
mean VA 
letters      
(±SD) 
12 month 
mean VA 
letters     
(±SD) 
Proportion of 
eyes 
maintaining 
≥76 letters at 
12-months                   
(%) 
P value 
(Proportion of 
eyes maintaining 
≥76 letters at 12-
months compared 
to baseline, First 
eye vs. Second 
eye) 
P value of 
first eyes vs. 
second eyes 
mean VA at 
baseline 
P value of 
first eyes vs. 
second eyes 
mean VA at 
12-months 
Baseline VA 
≥76 letters 
(Snellen 6/9) 
First         
eye 
8 
78.97                  
(2.45) 
64.24                   
(13.17) 
1/8                           
(12) 
0.05  
 
0.03 
 
0.02 
Second   
eye 
11 
81.87                  
(2.76) 
77.38                   
(8.01)  
9/11                           
(82) 
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4.4 - Discussion 
4.4.1 - Symptoms and visual acuity change of the second eye at baseline 
There is a high rate of second eye involvement in nAMD, and it may present as a 
bilateral, sequential disorder. (42) This study demonstrates that symptoms alone 
cannot be relied upon to indicate early second eye nAMD, with 53% of patients in our 
cohort being asymptomatic at diagnosis, which is higher than the 21.5% reported by 
Chevereaud et.al. (184) Neurological compensation mechanisms can result in 
patients being asymptomatic in the early stages of nAMD (62) and previous 
histopathological studies have identified CNV membranes in asymptomatic patients. 
(66) Home detection devices for macular disease, including preferential hyperacuity 
visual field testing and hand-held OCT scanners (185) (186) are being trialled, but 
are not yet employed as standard practice.  
 
Choroidal neovascularisation may exist for some time causing macular structural 
damage before becoming symptomatic or clinically detectable. (186) This 
emphasises the importance and utility of performing OCT to monitor the second eye 
of patients undergoing treatment for unilateral nAMD during their routine follow up 
visits in the clinic. Many patients (62%) developed nAMD in the second eye without 
an observable change in VA compared to the previous visit (62%). VA decrease of 
≥5 letters was used as a marker of CNV activity and helped guide retreatment 
decisions in pro re nata (PRN) and treat and extend protocols of the PrONTO and 
SUSTAIN studies. (129, 187) In this study the most prevalent clinical finding was the 
presence of IRF and/or SRF imaged with OCT, and in 33% of patients, this was the 
only clinical indicator of nAMD in the second eye at baseline. Previous studies have 
shown that OCT fluid is a reliable marker of active nAMD (188) and OCT changes 
can be sudden and unpredictable. (189) 
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4.4.2 – Visual acuity change of second eyes over 12-months 
Second eyes with good baseline acuity (>76 letters, or 6/9 Snellen VA) showed both 
a higher rate of maintenance of good VA and a higher mean VA at 12-months 
compared to first eyes, implying that early detection and treatment can help maintain 
vision (Table 12). This finding is consistent with a study by Ying et al which reported 
that a better VA at baseline correlated with a better final VA after treatment (190), 
suggesting that patients starting with a worse VA have an element of irreversible 
visual loss that cannot be rescued or stabilised with anti-VEGF therapy. Delay in anti-
VEGF therapy for CNV could result in the ingrowth of fibrocytes, leading to 
permanent loss of retinal tissue and function within a short period of time (186) in the 
form of disciform scarring, the most common outcome of AMD related CNV.  
4.4.3 - Anatomical outcomes of second eyes compared to first eyes 
The proportion of second eyes that were fluid free at 12-months (70%) was higher 
compared to the CATT study groups which were given ranibizumab monthly (43% 
fluid free at 12-months). (132) This finding is more significant when considering the 
higher proportion of cases with fluid at baseline in this cohort compared to CATT  
(92% in this study vs. 71% in CATT) and the fewer average number of injections in 
this cohort.  Furthermore, a higher rate of fluid resolution in second eyes compared 
to first eyes was observed in the same cohort of patients (70% vs. 41%, p=0.02) 
suggesting that early intervention can reduce the time taken to achieve a fluid free 
fovea, which may result in less irreversible structural damage to the retina. Recent 
guidelines suggest implementing a position of no-tolerance for OCT fluid (63) 
highlighting the importance of this reduced exudation. IRF in particular has been 
identified as a key baseline OCT feature indicating chronicity of CNV, and conferring 
poorer visual outcomes. (140) The rate of baseline IRF in this cohort was consistent 
with other reports (191, 192) with the second eyes demonstrating a statistically 
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significant lower rate at baseline and 12-months compared to first eyes (p=0.01, 
p=0.08). Early detection of nAMD in second eyes likely occurred in this cohort, 
thereby reducing the amount of exudative IRF occurring secondary to breakdown of 
the outer blood-retinal barrier (140), and subsequent irreversible retinal damage. This 
potentially explains the superior outcomes of second eyes in this cohort with good 
baseline VA at 12-months compared to first eyes.  
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4.4.4 - Study strengths and limitations 
The strengths of this study lie in the standardised diagnosis, treatment and regular 
follow up including OCT imaging at each attendance with a single physician at a 
single treatment centre. The regular monitoring of both eyes in this cohort with a 
mean of 47.6 ±19.8 days between visits prior to diagnosis of second eye nAMD may 
have reduced the delay between development and detection of second eye disease 
unlike other studies, which have a greater interval between data collection points. 
Assessing the outcomes of first eye and second eye disease in the same cohort of 
patients reduced the effect of heterogeneity in patient response to treatment. 
Selecting a cohort treated by a single physician reduced the potential effect of 
different diagnosis and management decisions.  Furthermore, the data relating to 
symptomatology of second eye disease has previously been given limited attention in 
the literature. 
 
Limitations of this study include the small sample size, however the inclusion criteria 
were narrow by design to examine the difference of first vs. second eye outcomes in 
the same patient. The technology of the OCT scanner was upgraded during the 
study period, which may have influenced the ability to detect fluid. The image 
resolution of the scans was improved, therefore the high rate of fluid-free patients at 
12-months is likely a reliable observation and more significant, as any fluid initially 
detected with a lower resolution TD-OCT scan would be seen on a higher resolution 
SD-OCT image.  
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4.5 - Conclusions 
This study demonstrates that a high proportion of second eyes with angiographically 
diagnosed nAMD are asymptomatic, with OCT providing the only clinical indicator of 
nAMD.  Reliance on symptoms, VA change and fundus examination as screening 
tools alone may delay detection and treatment of nAMD.  Early detection and 
treatment of second eye nAMD in patients with good VA may potentially result in 
better visual outcomes. This may be especially critical for the second eye when it is 
the better seeing eye. 
.   
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CHAPTER FIVE - General discussions and 
conclusions 
 
5.1 - Key findings and implications of the thesis research 
5.1.1 - Long-term ranibizumab study 
The LTRS has investigated and examined the 5-year visual, anatomical and safety 
outcomes of ranibizumab used to treat nAMD in a real world clinic setting. This 
cohort is more representative of the patient population encountered in routine clinical 
practice compared to clinical trials with more restricted inclusion criteria and follow-up 
protocols, and the follow-up period is much longer than most clinical trials, which are 
usually designed to test the efficacy of a new therapy or treatment regime.  
Ranibizumab treatment provided stability of VA for the majority of patients over 5-
years, (79.8% lost <15 letters) with an average of 30.8 injections. Eleven per cent 
maintained a >15 letter improvement compared to baseline at 5-years.  
There was significant variation in the number of injections required in the 5th year, 
with 36% of patients not requiring an injection, and 24% requiring 10-12 injections.  
This data therefore provides useful information for clinicians when counselling 
patients on the number of injections they will likely require in the long-term, and the 
real world visual outcomes. It also highlights that a large proportion of patients will 
require burdensome, regular long- term treatment, and also have greater exposure to 
the risks of treatment. 
The published LTRS paper (134) was the first to describe 5-year outcomes in a real-
world setting. To date, it remains one of the few “real world” studies published from 
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Australia, and is unlike other long-term studies (153, 154) in that it included a 
population of all patients who did continue treatment and monitoring for the entire 5-
years, providing an insight into the outcomes of a population with demonstrated long-
term compliance to the management of nAMD. The publication arising from the 
LTRS has been cited in a review of “real world outcomes”, (193) with the LTRS main 
visual acuity findings consistent with other studies. Although a disease guided, 
variable interval treatment model yielded clinically significant improvements in VA at 
all time points, they were inferior to clinical trials at 2-years, and that as a cohort, 
initial mean visual gains seen in the first 2-years are not maintained in the long-term.  
(193, 194)  However the mean VA change masks the findings that the majority of 
patients in the LTRS (79.2%) maintained their vision over 5-years (losing ≤15 letters).   
Another explanation for the inferior visual outcomes is that the real-world cohort 
included patients with Snellen VA >6/12 (meaning that the potential for VA gain was 
less, (ceiling effect of VA”), compared to most clinical trials.  
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5.1.2 - Second eye ranibizumab study 
This study showed that over 50% of patients are asymptomatic at the time of 
diagnosis of nAMD in the second eye whilst being regularly monitored with OCT 
scanning.   
In patients with good baseline visual acuity (>76 letters), visual outcomes were better 
in patient’s second treated eyes compared to their first, likely due to comparatively 
earlier detection and treatment (mean VA second eyes 77.38 ±6.2 letters vs. 64.24 
±13.2  letters at 12-months,p= 0.02) resulting in superior anatomical outcomes. 
Relying on symptoms, VA, and fundus examination as screening tools for early 
nAMD potentially may result in many treatable cases of subfoveal nAMD being 
missed. Patients presenting with symptoms due to nAMD are likely to have already 
suffered irreversible visual loss. (58, 60) Optical coherence tomography may provide 
the only clinical finding indicating the presence of nAMD.  This is one of few studies 
to assess the symptomatic status of nAMD patients with treatable CNV lesions, and 
the results provide a cautionary tale to clinicians who advise patients to only present 
for care of they become symptomatic.  Furthermore, it follows that with this finding; 
the second eyes of patients should undergo opportunistic OCT scans at every visit 
whilst attending for treatment in the first eye. 
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Patient’s second eyes also demonstrated superior anatomical outcomes.  Fifty-four 
per cent of second eyes had IRF at baseline compared with 83.7% of first eyes 
(p=0.01). IRF has been identified as a marker of occult CNV chronicity. (140) The 
OCT fluid free rate of second eyes at 12-months was 70% vs. 41% in first eyes 
(p=0.02). To the candidate’s knowledge, this is the first study to assess the 
anatomical outcomes of second eye disease in the same cohort of patients detected 
whilst undergoing treatment for the first eye. The study design helped to address 
inter-patient variability of treatment adherence and response to therapy.  
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5.2 - Challenges and limitations 
5.2.1 – Optical coherence tomography evolution of technology 
Due to developments in OCT imaging technology from time to spectral domain, SRC 
upgraded devices in the clinic to a Cirrus Spectral-Domain OCT system. This 
provided far superior imaging resolution, with the low-resolution Stratus system 
capturing 768 A-scans in a 6mm “star” arrangement vs. the Cirrus system capturing 
65536 A-scans in a 6mm cube. This transition to SD-OCT therefore reflected the 
adoption of improved imaging technology likely to confer clinical benefit for patient 
care secondary to improved image resolution, occurring in most ophthalmic practices 
world-wide.   Although unavoidable, this change presented challenges in performing 
comparisons between each of the machines for research purposes, affecting patients 
who started on the TD-OCT and progressed to the SD-OCT.   The anatomical 
boundaries measured are different between these machines, meaning that the CMT 
values from the SD-OCT would be higher than TD-OCT (see Chapter 3.4.5.1).  Since 
our results showed a significant CMT reduction between baseline scans (TD-OCT) 
and 5-year scans (SD-OCT) we did not perform a conversion, as it would not have 
changed the overall study finding. Several nAMD clinical trials also made the same 
transition from TD-OCT to a SD-OCT system mid-study, including the CATT study. 
(176)  
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5.2.2 - Retrospective design and missing data 
Given that both LTRS and SERS were retrospective case series’, there was 
inevitable missing data compared to a prospective study. This did not affect the 
visual acuity data or the safety data, as these records were complete.  Missing data 
was most common with OCT images, where the quality of some scans was too poor 
to contribute to the study. In the LTRS, 25 baseline OCT images were of too poor a 
quality to grade qualitative findings of IRF and/or SRF. In the SERS, 8/45 patients 
had at least one image that were not gradable in the first or second eye at baseline 
or 12-months, therefore the OCT analysis was restricted to the remaining 37 patients 
as it was critical to have a complete data set to analyse qualitative findings over time. 
Baseline FFA images were unavailable for grading in 18.2% (38/208) patient in the 
LTRS and 6.6% (3/45) of the SERS, as they were performed on a FFA camera 
where the images were no longer accessible at the time of the studies.  This did not 
materially impact on the key findings of the studies, as this data included the size and 
CNV lesion type, the analysis of which was not a primary aim of the thesis. Despite 
this data not being available, all patients commencing ranibizumab treatment had the 
appropriate FFA study at the time of diagnosis, confirming subfoveal nAMD. This is a 
requirement to access government subsidised ranibizumab (this criteria is outlined in 
Chapter 2). 
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5.3 - Future directions for research 
There remain unanswered questions regarding the indications for cessation of 
ranibizumab therapy once there is no active nAMD detected and the method and 
frequency of follow-up. Furthermore, the rate of recurrence of nAMD following the 
cessation of treatment is also unknown, along with the degree of irreversible visual 
loss following a recurrence.  Reliable predictors for successful cessation of therapy 
would be clinically meaningful. 
Baseline biomarkers for treatment response are also limited, although there is some 
emerging evidence that qualitative OCT findings can predict likely disease course 
and final visual outcomes. (140) The presence of SRF has been associated with a 
relatively benign disease course compared to IRF, and may be the best candidates 
for TaE regimes. (140) Prospective studies are needed to validate this idea.  
There is a need for research into the most effective and cost effective means for 
detecting new disease in the second eye, and recurrence in the first-treated eye.  
Emerging technologies in the form of home-based hyperacuity devices and hand-
held OCT’s may provide an alternative means for monitoring for recurrence, and 
second eye disease.  Alternatively, a collaborative OCT screening program in 
conjunction with other eye-care professionals (e.g. optometrists) may help facilitate 
early detection and thus optimise visual outcomes for asymptomatic patients.  
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5.4 - Conclusions of this thesis 
Ranibizumab is an effective treatment, with minimal serious ocular adverse events, 
or systemic serious adverse events when used in a real-world clinical setting over 5- 
years. This suggests that it can be used in the long-term for treatment of nAMD and 
other vascular retinal diseases.  
The individualised treatment regime resulted in stabilisation of VA in a large 
proportion of patients at 5-years.  This regime is similar to TaE, and is less 
burdensome than a monthly or PRN treatment protocol.  The VA results were inferior 
to clinical trials at the 1 and 2 year time points, consistent with other reports on real-
world outcomes.  Likely reasons include a reduced injection number, and a 
heterogeneous patient group, including patients with a baseline VA higher than 
clinical trial patients.  Despite this, the individualised regime has merit over a monthly 
or PRN regime given the vastly reduced number of injection, lessening the burden on 
patients, carers and health systems. 
Optical coherence tomography scans of both eyes at all visits to an eye-care 
professional may be warranted, as it can detect signs of nAMD prior to other clinical 
indicators. Second eye disease often occurs with no symptoms or change in VA. The 
maximal time delay between OCT evidence of nAMD and irreversible damage is not 
known, however early detection and treatment of second eye nAMD leads to superior 
outcomes at 1-year. This reduces the burden of visual loss to patients, carers and 
the health system. 
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Long-term ranibizumab study baseline data collection sheet 
 
 Signed informed consent:   
 
 
 
Which eye was initiated on Ranibizumab treatment on this visit? 
Right  /  Left Eye  / Both   
 
Was the second eye initiated on Ranibizumab at a later clinic visit?   Y / N     
If yes, complete “second eye baseline form”            
Baseline visit date:             /               /             .  
 
General information 
Date of birth:          /           /              Gender:  M  /  F                                     
 
Medical history 
 Smoker / Ex smoker / Non Smoker / Unknown 
 Relevant Ocular conditions/procedures during follow-up period:  Y / N      
 Right  
(Date) 
Left  
(Date) 
Notes 
Cataract     
Cataract Surgery    
YAG capsulotomy    
Other maculopathy    
Appendix A:  Long-term ranibizumab study baseline collection form Page 1/3 
Baseline  
Study ID: 
Data Collector:  
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 Relevant AMD treatment prior to follow-up period : Y /  N 
 
 
 
 
 
 
 
 Vitrectomy in study eye:     Y / N            Date:  ___________ 
 
 Relevant Medical history: Y / N 
 
 
 
Eye Exams Baseline Date 
     RIGHT    LEFT 
BCVA (Snellen)   
IOP (mmHg)   
 
 
Appendix A:  Long-term ranibizumab study baseline collection form Page 2/3
Treatment RIGHT  (Y/N) LEFT (Y/N) 
Focal laser (for AMD)   
PDT   
Avastin:   
 BL or Date of onset 
 Cardiovascular disease 
(CABG, Stent, AMI) 
 
 Stroke  
 DVT / PE / Other Blood clot 
event 
 
 Hypertension  
 Hypercholesterolemia  
 Diabetes   
 Others 
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        Study ID:_____ 
 
 
 
Appendix A:  Long-term ranibizumab study baseline collection form Page 3/3 
 
OCT machine (Baseline)             Stratus        Cirrus       Spectralis        Not Recorded 
 
FA Date: 
 
Fundus Photo Date: 
 RIGHT LEFT NOTES 
OCT Image: SRF / PED / Cystic / 
Fibrosis 
SRF / PED / Cystic / 
Fibrosis 
 
Central retinal thickness:   
 
CNV type: Classic / Occult / 
Mixed 
Classic / Occult / Mixed 
 
Lesion size (mm2)   
 
Fundus Photo: Haem  / Lipid Haem / Lipid 
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Long-term ranibizumab study - follow-up data collection sheet 
 
Study Eye:  RIGHT / LEFT 
Study Baseline Date:  
1 Month 
 Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
 
3 Month 
 Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
 
6 Month 
 Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
Appendix B:  Long-term ranibizumab study follow-up data collection form Page 1/4
Study ID:        
Patient DOB:        ____ 
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12 Month 
 Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
 
18 Month 
 Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
 
24 Month 
 Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
 
 
 
 
 
Appendix B:  Long-term ranibizumab study follow-up data collection form Page 2/4
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30 Month 
 Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
 
36 Month 
 Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
 
42 Month 
 Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
 
 
 
 
Appendix B:  Long-term ranibizumab study follow-up data collection form Page 3/4
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54 Month 
 Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
 
60 Month 
 Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
 
 
 Year 1 Year 2 Year 3 Year 4 TOTAL 
 
Number of 
Visits for 
AMD 
     
 
Number of 
Ranibizumab 
Injections in 
study eye 
     
 
 
 
 
 
 
 
Appendix B:  Long-term ranibizumab study follow-up data collection form Page 4/4
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Long-term ranibizumab study – adverse events data collection sheet 
*Only record ocular adverse events in the Study Eye 
 
 Adverse Event             Y  /  N          
AE  Date Count 
Pain 
 Floaters 
Sub-conjunctival Haemorrhage 
Lid Swelling 
Grittiness / Foreign Body Sensation 
Irritation to prep 
Epiphora   
Other _____________ 
  
↑IOP 
Endophthalmitis,  
Vitreous Haemorrhage,     
Retinal Tear,  
Retinal Detachment 
  
CVA 
 MI  
TIA 
  
Falls   
 
Appendix C:  Long-term ranibizumab study adverse events collection form Page 1/1 
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Long-term ranibizumab study – OCT grading data collection sheet  
 
 
Appendix D:  LTRS and SERS OCT data collection form Page 1/1 
Patient	Details	
Study	ID	 	 1st	Recorded	Lucentis	 	
Grader	 	 Study	Eye	 	
Grading	Date	 	 Visit	Date	 	
	 	 Visit	Number	 	
	 	 Verified		 	
	
Image	Quality	
Gradable	 0	
Forced	Grading	 1	
Ungradable	 2	
Not	Present	 3	
	
	
OCT	Machine	 	 Stratus		0	 Cirrus		1	 Spectralis		2	 	 Other		______	
	
1.	OCT	Data	
Central	Macular	Thickness	
(μm)	
	
Volume	(mm2)	 	
Comments	
	
	
2.	Intra-retinal	Fluid	(IRF)	
Absent	 0	
Questionable	 1	
Present	 2	
Outside	Central	 3	
Central	Point	Involved	 4	
CG	 8	
IRF	Thickness	at	Centre	Point	(μm)	 	
IRF	Max	Thickness	Along	Any	Scan	(μm)	 	
	
3.	Sub-retinal	Fluid	(SRF)	
Absent	 0	
Questionable	 1	
Present	 2	
Outside	Central	 3	
Central	Point	Involved	 4	
CG	 8	
SRF	Thickness	at	Centre	Point	(μm)	 	
SRF	Max	Thickness	Along	Any	Scan	(μm)	 	
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Second eye ranibizumab study baseline data collection sheet 
 
Second eye which underwent Ranibizumab treatment: 
Right  / Left Eye   
 
Baseline visit date for initiation of Lucentis in the second eye:     /      / 
Eye Exams 
     RIGHT    LEFT 
Symptoms   
Symptom duration   
BCVA (Snellen)   
IOP (mmHg)   
 
 
Appendix E:  Second eye ranibizumab study baseline collection form Page 1/
Fundus Photo, FA and OCT Outcomes 
OCT machine (Baseline)             Stratus        Cirrus       Spectralis        Not Recorded 
FA Date: 
Fundus Photo Date: 
 RIGHT LEFT NOTES 
OCT Image: SRF / PED / Cystic / 
Fibrosis 
SRF / PED / Cystic / 
Fibrosis 
 
Central retinal thickness:   
 
CNV type: Classic / Occult / 
Mixed 
Classic / Occult / Mixed 
 
Lesion size (mm2)    
Fundus Photo: Haem  / Lipid Haem / Lipid 
 
Study ID: 
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Second eye ranibizumab study follow-up data collection sheet  
 
 
Appendix F:  Second eye ranibizumab study follow-up data collection form Page 1/2
Study Eye:  RIGHT / LEFT 
Study Baseline Date:  
1 Month 
¨ Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
 
3 Month 
¨ Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
 
 
6 Month 
¨ Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
	
Study	ID:																	___	
Patient	DOB:								____	
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Appendix F:  Second eye ranibizumab study follow-up data collection form Page 2/2 
 
12 Month 
¨ Date of Visit:               /           /         .     
 RIGHT LEFT Notes 
BCVA    
Central Thickness    
 
Stratus                 Cirrus                 Spectralis             Not Recorded 
 
 
 
 
 
 
 
Number of Ranibizumab 
Injections in the second eye 
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